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The Chief Medical Officer (CMO) for the Department of Health requested an evaluation of the 
NIHR investment in Cochrane infrastructure and systematic reviews (SRs). The committee 
were tasked with examining NIHR investment in Cochrane in meeting the key clinical and 
policy questions in the NHS, taking into account the wide variety of global review producers 
and commissioners. The objectives of this evaluation were as follows: 
This report considers these objectives in six chapters.  This review had to be proportionate in 
resources, and therefore drew largely on readily available sources of evidence, including 
reports, interviews and the Committee's own expert knowledge of the field. This information 
was supplemented as considered necessary by the Committee, and a series of interviews with 
stakeholders was conducted. A researcher collated data following directions of the lead and 
the Committee. The Committee met regularly to discuss findings, data, interpretation and 
recommendations; and participated in recommendation formulation. The Committee 
responded to the objectives above in the following sections: 
1. The global landscape of systematic reviews 
Cochrane has had an enormous impact on SRs production since it was established, accounting 
for 6,906 reviews in issue 5/2016 of the Cochrane Library. The NIHR and its predecessors have 
provided funding to Cochrane since 1992 and the NIHR has committed £16 million funding 
for 21 CRGs over the current five year contract period (2015-2020), representing a total of 
40% of CRGs worldwide (21/52). Cochrane has made a significant contribution to other 
processes, including methods developments, and, indirectly, guideline production. Cochrane 
has been central to the development of the science of research synthesis, and Cochrane 
1. To review how the performance of systematic reviews could be improved. 
2. To review the broader landscape of systematic reviews and consider the role of 
Cochrane, and the NIHR investment, compared to other global providers of 
reviews; in particular in meeting the key clinical and policy issues facing the NHS. 
3. To review the performance of the NIHR funded Cochrane Review Groups (CRGs) 
and Cochrane UK: 
a. quantity and quality of outputs. 
b. impact in influencing NHS practice/policy and (in so far as is possible) NHS 
culture 
4. To consider current and planned developments in Cochrane, and how and if, NIHR 
might wish to continue to influence these, to ensure better value for the NHS. 
5. To consider the content and implementation of the Cochrane strategic plan in 
ensuring better value for the NHS. 
6. To advise on whether the current NIHR investment in Cochrane is well spent or 
should be allocated in other ways or to other areas. 
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participants have contributed to helping develop the unified transparent GRADE approach to 
guideline development. 
Recognition of the value of systematic reviews at a governmental level has resulted in much 
wider infrastructure investment across a range of SR producers in the UK. These are often 
focused around specific policy questions, eclipsing the total number of SRs produced by 
Cochrane. Technology Assessment Review (TAR) teams produce reviews for NICE around 
specific questions and NIHR has committed £38.5 million over five years from April 2016 to 
TAR teams. Worldwide, systematic reviews are now mainstream for academic medical 
research, and around 11,000 SRs are produced every year worldwide. 
Cochrane's continued contribution to the development of methods is important, but the 
product of the systematic review is less unique, given the many other SR providers. Cochrane 
reviews are unique in terms of a commitment in principle to keeping them up-to-date, but 
this has proven difficult to implement fully.  
Without a doubt, Cochrane is a reliable first port of call with a strong history, reputation and 
brand and is relatively inexpensive. However, there are many other SR producers in the UK, 
making up a large SR playing field. In order to maintain and strengthen its place, the 
Committee recommends that Cochrane should more clearly identify its niche and redefine 
where it fits in this changing environment.  
2. The performance of NIHR funded Cochrane Review Groups (CRGs)  




It was clear that there was considerable variation between reviews in terms of quality and 
between CRGs in terms of performance and coverage. Whilst there have been attempts to 
address these critical concerns through the efforts of the CRGs and the Cochrane Editorial 
Unit, the committee considered that this variation had not been addressed well to date. 
Quality is a critical point, which requires openness and transparency. Whilst quality of the 
7,000 Cochrane reviews is good relative to non-Cochrane reviews, not all of Cochrane reviews 
are good quality. One independent analysis showed that 88% of Cochrane reviews are rated 
to have a low risk of bias, compared to only 12% of non-Cochrane SRs, which is something 
Cochrane can be very proud of. However, specific groups of non-Cochrane reviews such as 
those for NICE and other HTA agencies are also likely to be rated at low risk of bias. 
Nevertheless, internal screening within the Central Editorial Unit of Cochrane has shown that 
5% of NIHR-funded SRs signed off by the CRG Co-ordinating Editor still required major 
amendments before they met methodological expectations.4 
 SR production 
 Quality (whether outputs were reliable, rigorous, readable and relevant to the NHS) 
 CRG managerial efficiency 
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Timeliness of review production remains a concern for the Committee. For reviews to address 
questions relevant to NHS decision-makers, they need to be completed for policy windows. 
Unfortunately delays in review production impairs an organisation’s ability to ensure policy 
windows are met. This also linked to problems concerning relevance of reviews and coverage 
of topics and assuring timely updating of high priority topics. Timeliness of reviews is essential 
to achieve impact, and requires CRGs to prioritise review production and updating carefully. 
Timely updating of reviews represents a significant challenge. During the 2014 assessment 
process, 1,250 reviews were assessed as requiring an update, which were either in-progress 
or awaiting sufficient resources to complete them. Coverage is impaired by reviews missing 
in important topic areas, and also because a number of important reviews are out of date. 
Level of interest in NIHR-funded CRG work is high; nine of the top 10 most accessed Cochrane 
reviews of 2014 were produced by NIHR-funded CRGs. This number of accesses refers to 
downloads of PDFs or HTML files from the Cochrane Library. An analysis of the impact of 
Cochrane SRs on policy examined the number of NIHR-funded CRG reviews cited in NICE and 
SIGN Guidelines published between 2013 and February 2016. This showed 415 Cochrane 
reviews from 19 of the 21 UK-based NIHR-funded Cochrane Review Groups were cited in 103 
guidelines (74 NICE; 29 SIGN).5 Whilst this shows guideline producers identify and cite 
Cochrane SRs, this does not directly demonstrate influence or impact on behalf of Cochrane.  
An enduring criticism of policy-makers and funders is that some CRGs consistently exclude 
other sources of effectiveness data when randomised controlled trials are absent; and that 
Cochrane do not carry out reviews in areas that are also important for policy development. 
Cochrane needs to more widely address the scope of evidence being used if it intends to be 
seen as the ‘home of evidence’; encouraging more focus on sources of data other than RCTs, 
including observational studies, indirect comparisons, economics, and adverse effects 
evidence. Of concern are empty reviews if they have overly restrictive inclusion criteria 
concerning the types of studies, such as only RCTs, in situations where other types of studies 
addressing the question exist.  
A study conducted in 2010 found that nearly 9% of all reviews published in CDSR had no 
included studies meeting the inclusion criteria.6 The study found that NIHR-funded CRGs 
produced 52% of all reviews on CDSR (2,249/4,320, based on data from Yaffe6) however these 
CRGs also contributed nearly 66% of all empty reviews (248/376, based on data from Yaffe6). 
The Committee identified mixed author experiences with CRGs. There were many expressions 
of positive experiences, there are also tensions between authors and CRGs. Some feedback 
about CRGs remains critical, especially where prospective reviewers are dismissed because of 
CRG workload and where long delays occur in dealing with protocols and draft reviews; this 
means that NIHR investment is put at risk where reviews cannot get through the editorial 
pipeline in reasonable time. The committee recommends that data about transit times from 
workflow should be included in NIHR monitoring requirements, and some benchmarks for 
turnaround established so performance can be measured against this. 
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Surveys of quality against Cochrane standards (MECIR), readability studies and the number of 
reviews that are signed off by editorial groups but then are pulled from publication by the 
Central Editorial Unit are not disclosed internally or publically. The Committee recommends 
public disclosure of CRG performance. A number of low quality Cochrane SRs exist and can be 
identified from existing and future MECIR and readability studies.  
These data provided invaluable insight into the CRGs who perform well consistently producing 
high quality reviews, and distribution of these indicators will help groups take remedial action, 
provide the CEU with an opportunity for dialogue, and NIHR to adjust funding in relation to 
performance. 
3. Cochrane’s impact on key clinical and policy issues in the NHS 
To date, Cochrane has had an impact on people, methods, policy, research, and health 
outcome. Cochrane is seen as a trusted source by healthcare professionals, clinicians, 
guideline developers, information producers and infomediaries.2, 7, 8 Cochrane evidence is 
also valued by health commissioners, policy developers, NHS managers and the public, 
however they find it more challenging to use in a practical sense. Consequently, they value it 
less than could be the case, leaving room for additional improvement.2 
For many, but not all, NHS institutions, Cochrane is a primary source of evidence; such 
apparent impact needs to be assessed in a meaningful way, and Cochrane should be more 
proactive in its planning or anticipation of impact.  
Impact will only happen if CRGs prioritise. Existing processes in Cochrane are helpful, but the 
Committee feels these could be more successful if there is a more explicit, transparent and 
centralised strategy that establishes what the Priority List is for and how the NHS needs can 
be incorporated into CRG priority review decisions.  Prioritisation needs to continue to build 
on examples of good practice and the organisation needs to challenge parts of Cochrane that 
are not active or transparent in prioritisation, or implementing existing priorities, especially 
in processes that acknowledge NHS needs. Cochrane has had, and continues to have, 
substantial collateral impact having influenced methodological developments. Looking 
forward, Cochrane needs to proactively embrace other approaches (use of best available 
evidence; economic data) within its full systematic reviews. 
The Committee is well aware that Cochrane is a worldwide organisation and that the activities 
of UK based CRGs have a worldwide focus. Funding UK based CRGs gives benefits worldwide, 
and simultaneously the NHS benefits from Cochrane work done elsewhere in the world. 
However, some of Cochrane’s activity does not have an impact, often due to timing. Cochrane 
should be encouraged to consider upcoming guideline questions to identify review title 
priorities. It is essential to get an overall profile of Cochrane impact as a whole, rather than 
focussing on single impactful reviews. Furthermore, Cochrane has a number of resources, 
generated with support of NIHR funding, which are not fully accessible, such as specialised 




More involvement of Cochrane Consumers, and other stakeholders in the whole systematic 
review process, but specifically question formulation, scoping, outcomes, and dissemination 
products (beyond the Plain Language Summary) may improve the relevance and uptake of 
reviews. Increasing uptake may improve impact of reviews. Questions remain whether CRGs 
are proactive enough to sustain these impacts, and whether reported impacts are due to 
serendipity, or due to planning. There are many resources and examples of public 
involvement in research that Cochrane could build on in this regard. 
Cochrane UK (formerly the UK Cochrane Centre) has played a crucial role in training and 
accomplishing culture change to using evidence in decision making in the NHS. Cochrane UK 
should continue with further training of NHS staff, and should engage with both NHS 
prioritisation initiatives and CRGs in order to play a major facilitating role to match Cochrane 
review production to topics relevant to the NHS, making sure these reviews are prepared in 
a timely manner and are being kept up-to-date. 
4. The economic impact of systematic reviews 
The economic impact of SRs was considered in four case studies. The case studies were highly 
selective, and selective information was used for each case study. The case studies showed 
that for Cochrane to represent value for money it would need to recommend only a small 
number cost-effective interventions a year. However, the Committee considered that 
justifying all Cochrane activities and reviews as worthwhile on the back of a small number 
that have impact is a weak rationale. It would be useful to see more routine Cochrane work 
that uses economic evaluation to determine whether reviews can lead to savings in the NHS. 
Cost savings are not the only possible outcome, methods may show effective treatments 
which cost the NHS money. It also should be borne in mind that reviews exist that evaluate 
standard practice, which could result in savings to the NHS. On average, Cochrane reviews 
come out with relatively low unit costs, but these estimates need to take relevance and 
quality in to account, and the time of health or academic staff carrying out the review. 
5. Current and planned developments in Cochrane and stakeholders’ views 
The Committee asked NIHR to commission some stakeholder interviews (34) to assess the 
views and experiences of Cochrane review users and producers based in the UK and the NHS.2 
The results are summarised later in Chapter 5.  The themes, in most cases, added weight to 
evidence in this review and the findings of Cochrane and Wiley commissioned stakeholder 
exercises7, 8 (which were worldwide, with less UK and NHS focus).  The overlaps in findings 
between the three exercises are summarised below*;   
Cochrane brand; trusted source of evidence with independence and addressing conflicts of 
interest.  
Quality of Cochrane reviews; review users strongly value the rigour, transparency and clarity 
of Cochrane reviews, but there was less consensus (across all stakeholder exercises) about 
                                                          
* Unless stated these refer to all three of the included exercises.2, 7, 8 
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value of access to the underlying source data and widening source data (health economics 
and real world data from different healthcare settings). 
Cochrane relevance; many find Cochrane reviews relevant, although it can be frustrating 
when there is no conclusion, or reviews are 'empty'.  For some groups in the UK 
(commissioners, policy makers and consumer/patient organisations) they find reviews less 
relevant. Two reports conclude that a range of stakeholder representations in review 
processes and production would potentially help address relevance issues. 
Priority setting; two of the exercises highlighted the need for  a more systematic use of 
priority setting and stakeholder representations (i.e. health professionals, consumers, 
patients and the public, funders, policy makers and guideline developers) utilising existing and 
current health priorities, objective data on burden of disease and healthcare, and identified 
gaps in published evidence. 
Dissemination of Cochrane reviews and products; Cochrane could offer more products or 
services that would promote review uptake among different groups, customised according to 
target group e.g. commercial media channels, partnerships with medical journals, briefing 
papers for policy makers, professional and community networks, high profile bloggers.  
Comments were also made on presenting reviews with narrative synthesis, clinical 
summaries, graphical content, contextual information, and emphasis on the interpretation of 
the evidence (including metrics used by practitioners). An ongoing challenge is for Cochrane 
to be able to respond to the changing needs of the review user community. 
Cochrane’s Strategy to 2020 should determine and highlight Cochrane’s niche and unique 
selling points, and provide clear direction to realise these. Cochrane should work on 
developing expertise and processes to get better and quicker at producing reviews. Cochrane 
should revisit some of its goals as there seem to be many different objectives in many areas. 
The Committee feels that an explicit focus is needed on relevance to patient care, as a primary 
goal. The Committee recommends that Cochrane keeps full SRs as its primary product and 
makes sure that activities to develop new products do not have a negative impact on timely, 
relevant full systematic reviews. This is echoed in stakeholder feedback; a new output is not 
required, just the existing product delivered quicker and with high relevance. 
Centralisation versus decentralisation (roles of the Central Editorial Unit and the CRGs) is a 
core consideration for Cochrane’s future and should be transparently and swiftly discussed. 
Clarifying areas in CRGs for consistency and areas for flexibility is critical to Cochrane’s roles 
and functionality moving forward.  
The nature of funding dictates where responsibilities lie and funding sources should be openly 
considered when thinking about future direction of travel, capacity and accountability. Key 
considerations should focus on measures of impact; emphasising the need for groups to plan 




 Many recommendations in this report may be in line with, or in progress with, the 
Cochrane strategy to 2020, however the Committee feels that progress needs to 
speed up, be more definite and more transparent and linked to a clear vision of 
Cochrane’s place in the world of systematic review production. 
 The Committee recommends to continue funding Cochrane. However, this funding 
should be linked to key performance indicators to ensure optimal value for money. 
These should focus on measures of impact; emphasising the need for groups to plan 
and think more strategically moving forward in order to maximise impact in the NHS. 
 Impact should be assessed in terms of impact on policies, practice change, culture 
change, and methodology change.  For realising such impact, improving 
communication with the public, health professionals and policy makers will be key for 
Cochrane UK, individual review groups, and Cochrane worldwide. 
 If warranted, variation of funding be it either increased or decreased should be swiftly 
implementable. If Cochrane improves on addressing NHS priorities an increase of 
funding makes sense. 
 A revised structure of CRGs could impact dramatically on efficiencies, outputs and 
future funding models, and should be explored, and pursued more proactively by 
Cochrane. For example fewer, larger groups could overhaul efficiencies.  
 In the Committee’s opinion, the past has shown good value. With critical changes in 
quality, prioritisation and changing structure, the organisation could maintain its 
important role. Therefore, key performance indicators should be crucial in securing 
funding.  
Recommendations and considerations for NIHR Cochrane funding 
Recommendations to Cochrane 
Cochrane should more clearly identify its niche and redefine where it fits in the changing 
environment of SRs. The Committee recommends that Cochrane keeps full SRs as its primary 
product and makes sure that activities to develop new products do not have a negative impact 
on timely, relevant full systematic reviews. Continue focus on maintaining and improving 
quality in the domains: 
 Relevant: relevance to the NHS (use best available evidence, try to avoid empty 
reviews) 
 Reliable: includes the review conclusions reflecting the findings 
 Rigorous: low risk of bias 
 Readable: clearly written for identified audiences 
Cochrane should improve transparency around assessments of quality and CRGs’ 
performance; continue funding/supporting well performing CRGs, stop funding/supporting to 
poorly performing CRGs, consider reorganisation of NIHR-funded CRGs (see options below). 
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Address priority setting for new reviews and updating existing reviews: 
 Consider a more explicit, transparent and centralised prioritisation strategy, while 
maintaining wide coverage in line with NHS and global priorities 
 Establish how the NHS’ needs can be incorporated into CRG priority setting   
 Cochrane UK should help to improve the performance of CRGs in meeting the 
evidence needs of core UK relationships 
Address timeliness of reviews and updates: 
 Reviews should be as much as possible ready and up-to-date at the point in time of 
decision-making and policy windows 
 Implement changes aimed at faster editorial turnaround times 
Recommendations to NIHR 
Evaluation of performance 
NIHR funding to CRGs should be based on each group’s performance in relation to quality 
(relevant, reliable, rigorous and readable), priority setting, relationship to the NHS, and 
timeliness. 
NIHR should work with Cochrane UK and the Editor in Chief’s Office and CRGs in implementing 
the strategic plan,9 in relation to improving CRG performance. Evaluation of performance by 
NIHR funded Cochrane entities has in the past focussed too much on quantity of outputs such 
as numbers of reviews and updates. A shift is needed towards more focus on impact for the 
NHS. Concrete options may include: 
 Use measures of quality (relevant, reliable, rigorous and readable)  
 Use measures of timeliness, including faster editorial turnaround time at every step 
of the editorial processes 
 Use measures that demonstrate activities to improve NHS relevant priority setting 
 Put more emphasis on metrics that capture NHS impact via all the supporting agencies 
and organisations  
Possible future funding arrangements 
The Committee suggests a number of options for future funding arrangements: 
 Increase incentive awards, these have been shown to have considerable impact on 
timeliness. Consider linking the awards to NICE and other existing NHS priorities; 
Cochrane UK (see below) should play a role in this process. 
 Have fewer but larger groups, while maintaining wide coverage in line with NHS and 
global priorities. This will yield economies of scale and increase consistency. 
 Stop funding underperforming groups, only fund well performing groups. 
 Let groups compete for funding and award funding proportionally to NHS relevance 
and timeliness. Cochrane UK could play a major role in this allocation process. 
Future role of Cochrane UK 
Cochrane UK (Cochrane Centre in Oxford) should play a more central role in developing the 
strategy, implementation and monitoring, to improve CRG performance, as specified above. 
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In addition, Cochrane UK has a major role in assuring prioritisation and timeliness to meet the 
needs of the NHS. This can be done by being an intermediary between for example NICE, 
medical charities, the NHS and Cochrane Groups. Formal liaisons with NICE and relevant NHS 








Systematic reviews (SRs) are the cornerstone of all new medical research and health policy 
ensuring that the best available evidence is used to inform decisions in health and care 
services. Since 1992, the National Institute for Health Research (NIHR, formerly NHS Research 
and Development) has funded Cochrane UK’s systematic reviews infrastructure and 
supported systematic reviews across a number of programmes. NIHR currently spends 
approximately £6m a year supporting Cochrane UK and 21 UK Cochrane Review Groups 
(CRGs) out of 52 worldwide. 
Given the changes in healthcare and needs of the UK National Health Service (NHS) and policy 
makers, the Chief Medical Officer (CMO) for the Department of Health, has requested an 
evaluation of the NIHR investment in Cochrane infrastructure and systematic reviews. An 
independent committee has been formed to lead the evaluation, which includes Professor 
Jos Kleijnen (Chair), Professor Paul Garner, Dr Phil Alderson, Ms Sally Crowe, Dr Jane Aubin, 
and Professor John Cairns. 
The evaluation will consider the health and economic impact of Cochrane reviews from 2005-
2014 by assessing the quantity, quality and impact of reviews on policy, practice and research, 
their relevance to the NHS, and the wider benefits which contribute to the return on the NIHR 
investment. 
Objectives 
1. To review how the performance of systematic reviews could be improved. 
2. To review the broader landscape of systematic reviews and consider the role of 
Cochrane, and the NIHR investment, compared to other global providers of reviews; 
in particular in meeting the key clinical and policy issues facing the NHS. 
3. To review the performance of the NIHR funded CRGs and Cochrane UK: 
 a. quantity and quality of outputs. 
b. impact in influencing NHS practice/policy and (in so far as is possible) NHS culture. 
4. To consider current and planned developments in Cochrane, and how and if, NIHR 
might wish to continue to influence these, to ensure better value for the NHS. 
5. To consider the content and implementation of the Cochrane strategic plan in 
ensuring better value for the NHS. 
6. To advise on whether the current NIHR investment in Cochrane is well spent or should 
be allocated in other ways or to other areas. 
Better reviews: relevant, timely and high quality 
In 2013 at the Cochrane UK and Ireland 21st Anniversary Symposium, the CMO Dame Sally 
Davies reflected on whether Cochrane has successfully met the challenges identified by 
Archie Cochrane in 1979. She set out her perspective of the challenges faced by Cochrane in 
the future, and gave advice on how Cochrane could adapt to meet these demands in a 
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changing environment.10 She made the point that Cochrane reviews in the UK represented 
very good value, at an estimated cost of approximately £15,000 of infrastructure funding for 
every new or updated systematic review. 
The recognition of the role of volunteers and contribution from other funders was key in 
attaining such value for money. There was considerable variation in outputs and activity 
between the different NIHR-funded CRGs, with the numbers of new systematic reviews 
produced by UK CRGs ranging from 1 to 30 in 2011. The CMO emphasised the challenges 
ahead for Cochrane, as well as the need for better reviews that are relevant, timely and of 
high methodological quality.  
Table 1: Key challenges facing Cochrane 
Patient involvement 
The NHS Constitution gives patients the right to join in and participate with all aspects of 
the research cycle from question formulation and importance to dissemination and 
implementation. Self-management of long term conditions and prevention of lifestyle-
related ill-health highlight the importance of patient involvement. The Collaboration must 
ensure that there is effective public and patient involvement to identify the patient-
relevant questions for Cochrane reviews and patient important outcomes. In the UK there 
is an established network and infrastructure of public involvement in research and in the 
NHS, with a co-ordinating centre based in the University of Southampton, Wessex 
Institute.  Medical research charities also advocate for patient needs and increasingly 
involve patients in their research strategy development and commissioning.  Increased 
collaboration with INVOLVE, the public involvement processes and networks in the NIHR, 
and the Association of Medical Research Charities are an important way for Cochrane to 
meet this challenge. Project ACTIVE by gathering examples of good practice within 
Cochrane but needs also to embrace what is happening outside Cochrane and where 
there can be enhanced collaboration. The UK remained the global leader of international 
Cochrane activity and NIHR was the leading funder. Attempts have been made by the 
CMO to encourage other countries to increase their funding to help the Collaboration go 
forward. The Collaboration must ensure that the questions addressed by reviews are not 
only interesting to researchers, but also questions that matter to the public, patients, and 
the frontline practitioners delivering health care. 
Collaboration with NICE 
Systematic reviews are essential building blocks for guidelines and guidance.10  Seventy-
three percent of NICE guidelines published from 2008 to 2013 referenced Cochrane 
reviews (range: 1 to 46 Cochrane reviews). A review of nicotine replacement therapy 
(NRT)11 produced by the Cochrane Tobacco Addiction Group demonstrated considerable 
impact in the field of public health. The NRT review11 was cited in NICE Guidance on brief 
interventions and referral for smoking cessation,12 as well as being cited by the WHO as 
high quality evidence of effectiveness. As a consequence of the review,11 NRT was added 
to the WHO List of Essential Medicines.13 
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Prioritise to topics of greatest importance 
Cochrane faces challenges as the UK population is enlarging and ageing, and there is a 
demanding financial situation. Combined, these factors place significant pressure on the 
NHS, placing greater importance on prevention, including screening and vaccination. 
Lifestyle-related ill-health and self-management must also be addressed. Higher-value 
health care is required, and potentially austerity will drive real innovation. The role of 
NIHR as a key Cochrane funder means that the focus should be on the public and NHS. 
This focus may be valid worldwide, however efforts should be prioritised into areas of the 
greatest importance for health and healthcare. Utilising existing priority sets that have 
this focus such as the James Lind Alliance are a good start but review groups may and 
need to undertake their own dialogue and process for establishing priorities, and there is 
no current agreed gold standard for ways to go about this.  The Cochrane Prioritization 
Methods Group has relevant resources to assist review groups, but a better shared 
understanding of what the central Cochrane Priorities List is for, and about, would enable 
this objective to be realised more fully.14 
Keep more reviews up-to-date 
Cochrane used to be the only player in the systematic review market, but now there are 
others such as the World Health Organisation (WHO), the Agency for Healthcare Research 
and Quality (AHRQ) and the American College of Physicians (ACP), who produce either 
standalone systematic reviews or reviews underpinning guidance. Cochrane's unique 
selling points are ongoing updates of reviews, completeness for certain topics, and its 
thread into the health service. Often real practitioners are undertaking reviews. NICE have 
started to carry out their own reviews, when an available and up-to-date Cochrane 
systematic review is not available. In 2012, the Collaboration investigated some of the 
issues around updating Cochrane reviews.15 Only 36% of systematic reviews in the 
Cochrane Database of Systematic Reviews (CDSR) were deemed to be up-to-date. Within 
the Collaboration, there is a view that reviews that are only of historical interest should 
be labelled as such. Priority should be given to the more important reviews, some of 
which will need updating more than every two years. Should a significant trial come out, 
there may be a need to update a review very quickly to ensure responsiveness and 
appropriate prioritisation.15 
Prepare reviews more rapidly 
The same Cochrane editorial15 gave the median production time as 23 months from 
protocol registration to publication. For some priority topics, two years might seem an 
unreasonably long time to wait for an answer to a question. When reviews are 
commissioned using programme grants and undertaken by professional reviewers, timely 
returns are expected and required. 
Use best available evidence, beyond RCTs 
In some circumstances, the best evidence available to answer a question may not come 
from an RCT. The Cochrane Non-Randomised Studies (NRS) for Interventions Methods 
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Group's role is to advise the Cochrane Steering Group to set a policy/formulate guidance 
about the inclusion of non-randomised studies (NRS) of the effectiveness of health care 
interventions in Cochrane Reviews.16 
Source: CMO (2013)10 
These points will be returned to in Chapter 6. The Committee will address the key issues facing 
Cochrane in the future, and propose strategic options for the consideration of commissioners, 
funders and Cochrane itself. 
Methods and sources to inform the evaluation process 
This review had to be proportionate in resources, and therefore drew largely on readily 
available sources of evidence, supplemented as considered necessary by the Committee. The 
time period covered by this report is 2005-2014, and data were considered for inclusion up 
to Spring 2016. The Committee acknowledges that some of these data will soon be or already 
are out of date. These sources included: 
 Factual output figures from the last NIHR quinquennial review (QQR) of Cochrane 
funding and more recent annual reports. 
 Relevant recent publications, e.g.: “The impact of Cochrane Reviews: a mixed-
methods evaluation of outputs from Cochrane Review Groups”3 and “The Cochrane 
Collaboration: an institutional analysis.”17 
 Bibliographic information 
 Stakeholder interviews and two other stakeholder reports commissioned by Cochrane 
and Wiley 
 Impact statements identified from NIHR funded CRGs including details of relevance 
for and impact on national UK guidelines from NICE, SIGN etc.  
 Economic impact of selected reviews 
 A survey of NHS patients and practitioners about the relevance to the NHS of NIHR 
funded CRG outputs 
 Quality of Cochrane reviews: assessments of the quality of Cochrane reviews with the 
ROBIS checklist18 against Cochrane’s MECIR checklist.19 
 Document review: using Cochrane policy documents, assessing progress towards 






CHAPTER 1 – SYSTEMATIC REVIEWS IN HEALTH: THE GLOBAL 
LANDSCAPE 
Overview 
As a first step in evaluating Cochrane's contribution and value to UK and international SR 
production, this chapter will describe the various organisations, funding streams, 
commissioners and programmes engaged in the ever-changing SR environment. Points 
covered in this chapter will include: 
 The dramatic increases in SR production over the last two decades 
 Cochrane as one of many in the UK and internationally preparing SRs 
 UK's contribution to the Cochrane landscape 
 UK funding in other SRs programmes 
Systematic reviews (SRs) aim to identify, evaluate and analyse the best available evidence in 
a transparent, methodical and reproducible way, and play a vital role in informing decision 
making. 
Since the first use of the phrase "systematic review" (PubMed20), international publication 
rates of SRs have increased exponentially in recent years, from 232 in 1990 up to 11,314 in 
2015 (PubMed estimate based on adapted Bastian21 approach).   
Figure 1: Estimated publication rate of systematic reviews from 1990-2014 [data collected 
24.3.15] 
 
Figure 2 presents the cumulative prevalence of Cochrane reviews and protocols (excluding 
withdrawn publications) and illustrates a similarly marked increase in the number of reviews 
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Figure 2: Cochrane Database of Systematic Reviews: total Cochrane Reviews and Protocols* 
 
 
Source: Cochrane (2014)22 *Cochrane Reviews can be withdrawn from the active database when 
they become out of date or are replaced by new Cochrane Reviews in a similar subject area.  
Further analysis conducted for this report (see Appendix 3: KSR Evidence database 
bibliometric analysis), identified 18,420 potential SRs.23 For all SRs retrieved with a publication 
year of 2010-2015 (n=18,420), 6% (n=1,153) were published in the Cochrane Database of 
Systematic Reviews,24 and 94% (n=17,267) were published in a different format, such as 





Figure 3: Percentage of all SRs retrieved produced by Cochrane and other producers (total = 
18,420; 2010-2015) 
 
Source: Kleijnen Systematic Reviews Ltd (2016)23 
The contribution Cochrane Review Groups (CRGs) made to publications of SRs varied across 
topics. Bibliographic analysis of publication distribution across a sample of five separate 
topics, showed that Cochrane reviews made up between 3-11% of published reviews. 
Figure 4: Proportion of Cochrane reviews identified for specific topics (2010-2015) 
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The topics of mental health and diabetes both contributed a yield of 3% Cochrane reviews 
(257/7,411, and 72/286 respectively). The lung disease and pain fields had the highest 
percentage of Cochrane reviews at 10% and 11% respectively (403/4,176, and 373/3,463). 
These data illustrate Cochrane's comparative role in the production and publication of SRs in 
the global marketplace, and indicate how competitive review production is becoming.25 
This report will focus on reviews on health and health-related topics, however systematic 
reviewing is increasingly being adopted outside of health in education, social care, agriculture 
and other areas of policy-making.26-30 Within the UK, and progressively on an international 
basis, guidelines are increasingly becoming 'evidence-based' and many guidelines and 
guidance publications are underpinned with systematic reviews.31 Therefore a great deal of 
SR production and activity is involved in guidelines production and this will also be included 
in this chapter. 
Increasingly public and patient perspectives and information needs have become important 
factors to be considered when commissioning and undertaking reviews. User and patient 
experiences can be invaluable sources from review inception to uptake and dissemination. 
Ensuring appropriate topics are prioritised for review, and that the research questions 
address interventions and outcomes that are relevant to patients, their carers, and consumers 
in general, depend on consultation with and involvement of users and patients.32 In addition 
to consideration of patient experiences and insights, users and patients can be encouraged 
to become involved as participants in the production of reviews, for example providing input 
to ensure the message of reviews are clearly accessible and easy-to-read by a wide 
audience.33, 34 
Cochrane has a rich history of involving patients and the public (consumers) in their review 
processes and this is something to celebrate; however practice across Cochrane varies and, 
with some notable exceptions, it has not kept pace with the world of Patient and Public 
Involvement in clinical research outside Cochrane.  In addition the current cohort of UK based 
Cochrane Consumers are unlikely to sufficiently represent NHS users and their priorities. 
With some exceptions consumer contributions are largely made by commenting on abstracts 
and Plain Language Summaries.35 However the recent Consumer Structure and Function 
review,7 and stakeholder consultations has underlined the need to expand this contribution 
to span the systematic review process, and Strategy 20209 supports this ambition.  Project 
Active which started just at the inception of this review seeks to collect and share examples 
of good practice in consumer involvement in Cochrane and it remains to be seen how much 
of this ambition will be translated into more widespread activities and impact on reviews. 
Organisations funding or preparing systematic reviews in the UK 
SR funding streams in the UK are complex, with multiple programmes funding different 
providers to produce SRs, health technology assessments, technology appraisals and 
guidelines. Table 2 below provides an overview of the key funders, SR producers, outputs and 
the relationships between them. Where available, an indication of funding allocations is 
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given. A more detailed description of the main funders, SR producers and their related 
outputs is presented in Appendix 1. Further ways of accessing existing systematic reviews are 





Table 2: Summary of organisations funding or preparing systematic reviews in the UK 
 Programme Remit Approximate 
Annual Budget 
(£) 
NIHR SR Programme Budget to support the updating of existing SRs, and the 
production of new SRs. Funding is allocated through several 
work streams (listed below). 
£13.6m 
 Cochrane Review Groups (CRG) Conduct of SRs and provision of editorial support and peer 
review. 
£3.2m 
 Cochrane UK Does not undertake SRs, but supports CRGS and other to do 
so. 
£0.8m 
 Cochrane Project funding   
 Cochrane Programme Grants Provision of high-quality new and updated SRs of direct benefit 
to users of NHS in England. Each grant is spread over 3 years 
(up to £140,000 max p.a.) 
Approximately 10 grants are awarded each year. 
£1.4m 
 Cochrane Engagement Awards To strengthen engagement between Cochrane SR producers 
and SR users within the NHS. 
£0.8m 
 Cochrane Incentive Awards Facilitation and acceleration of SRs that are already planned or 
underway. 
£5,000 per award 
 Complex Review Support Unit Provision of specialist expert advice to those producing 
methodologically complex SRs. 
£0.4m 
 TARs Conduct of SRs, reviews of economic evaluations and cost-
effectiveness models to inform DARs and MTAs. Conduct of 
STAs and HSTs to inform decision-making. 
£8m 
 HTA Funds independent research for the NHS about clinical 
effectiveness, cost effectiveness and impact of healthcare 
interventions. Primary studies and SRs. 
£74m 
 HSDR Production of rigorous, relevant evidence to improve 




 Programme Remit Approximate 
Annual Budget 
(£) 
support decisions by managers and clinical leaders. Projects 
may include SRs. 
 PHR Funds research to generate evidence to inform delivery of 
non-NHS interventions to improve public health and to reduce 
health inequalities. Projects may include SRs. 
£9.9m 
NICE Clinical Guidelines Support provided by the National Co-ordinating Centres 
(NCCs); work involves SR of evidence. 
N/A 
 Social Care Guidelines Support provided by the National Co-ordinating Centres 
(NCCs); work involves SR of evidence. 
N/A 
 Public health Work involves SR of evidence. N/A 
DH Policy Research Programme Commissions timely, cutting edge research focussing on the 
current needs of policy makers and ministers. Both primary 




 Conduct of SRs and methodological work. Financial support 
from a range of funding sources. 
N/A 
Charities  Conduct or commissioning of SRs, to utilise primary research 




 Conduct of SRs, meta-analyses, network meta-analyses and 
health economics outcomes research. Outputs might be 





 As part of continuing professional development (CPD) 
activities. 
N/A 




Organisations funding or preparing systematic reviews globally 
A range of organisations are involved in systematic reviews globally, some important players are mentioned below. Cochrane has existing 
partnerships with most of these groups. These are described in Appendix 1. 
Table 3: Summary of organisations funding or preparing systematic reviews globally 
Programme  Remit 
Cochrane worldwide  Conduct of SRs and provision of editorial support and peer review. Varied sources of 
funding from multiple finders. 
Joanna Briggs Institute  Conduct of SRs and provision of support to others undertaking SRs. Provision of 
methodological expertise and develops new methods. 
International HTA 
organisations 
INAHTA Collaborative network of international HTA agencies; encourages information sharing 
about HTA methods and encourages co-operation between agencies. 
 HTAi Professional society representing anyone involved in HTA and SR production and use. 
Forum for collaboration and sharing of expertise. 
 Regional and 
national HTA 
organisations 
Other collaborative networks on a regional or national basis. 
Guideline organisations GIN Collaborative association of organisations and individuals involved in the development and 
implementation of evidence-based guidelines and health care information. Does not 
conduct SRs, but encourages information sharing and methodological development. 
Governmental  Conduct or commissioning of research to inform decisions and policy-making in education, 
health, infrastructure social care, and humanitarian aid. Projects may include SRs. 
Commercial agencies  Conduct of SRs, meta-analyses, network meta-analyses and health economics outcomes 
research. Outputs might be unpublished, published, or used to compile regulatory 
submissions 
Academic Groups  Conduct of SRs and methodological work. Financial support from a range of funding 
sources. 
Charities  Conduct or commissioning of SRs, to utilise primary research and produce SRs to reinforce 
a relevant and reliable message. 
Healthcare professionals  As part of CPD activities. 
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Cochrane Review Groups 
SRs conducted by Cochrane are undertaken by 52 
Cochrane Reviews Groups (CRGs)36 worldwide, of 
which 21 currently receive infrastructure costs 
funded by the NIHR,37-39 and 24 have an editorial 
base in the UK.40  
Table 4: NIHR-funded Cochrane Review Groups 
Cochrane Review Group Web address 
1. Airways http://airways.cochrane.org/  
2. Bone, Joint and Muscle Trauma http://bjmt.cochrane.org/  
3. Cystic Fibrosis and Genetic Diseases http://cfgd.cochrane.org/ 
4. Dementia and Cognitive Improvement http://dementia.cochrane.org/  
5. Common Mental Disorders http://cmd.cochrane.org/  
6. Ear, Nose and Throat Disorders http://ent.cochrane.org/ 
7. Epilepsy http://epilepsy.cochrane.org/  
8. Effective Practice and Organisation of Care 
(EPOC) http://epoc.cochrane.org/ 
9. Eyes and Vision http://eyes.cochrane.org/  
10. Gynaecological Cancer http://gnoc.cochrane.org/ 
11. Heart http://heart.cochrane.org/ 
12. Incontinence http://incontinence.cochrane.org/ 
13. Injuries http://injuries.cochrane.org/  
14. Neuromuscular Disease http://neuromuscular.cochrane.org/ 
15. Oral Health http://ohg.cochrane.org/about-us 
16. Pain, Palliative and Supportive Care http://papas.cochrane.org/ 
17. Pregnancy and Childbirth http://pregnancy.cochrane.org/ 
18. Schizophrenia http://schizophrenia.cochrane.org/ 
19. Skin  http://skin.cochrane.org/ 
20. Tobacco Addiction http://tobacco.cochrane.org/  
21. Wounds http://wounds.cochrane.org/  
Source: NIHR Evaluation Trials and Studies (2015)40 
A further four CRGs, based in the UK, are funded by commissioners other than NIHR: 




There is also field-based activity that is not funded through NIHR. 
                                                          
 During 2015 the Cochrane Infectious Diseases Group took over the editorial base of the HIV/Aids Group. 
Sources that pre-date this change referred to 53 CRGs, and sources consulted after 2015 referred to 52 CRGs. 
Funding 
NIHR have committed £16 million 
funding for CRGs over the five year 
contract period (2015-2020). 
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Global landscape of systematic review production: Main points 
 Cochrane has had an enormous impact on SR production over time 
 NIHR investment has made this possible for Cochrane 
 Cochrane contributors have made an important contribution to methodology and 
other processes, advocating change and improving guideline production 
 There are many other SR producers in the UK, making up a large systematic review 
playing field  
 On average the cost of Cochrane reviews to NIHR is low (around £15,000) 
compared to TARs (£175,000) but this does not take into account quality or 
relevance of the review product 
 Cochrane is a reliable first port of call with a strong history, reputation and brand.  
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To assess and appraise the performance of NIHR-funded CRGs and Cochrane UK, this 
chapter will explore the outputs and activities of the CRGs, issues surrounding quality 
assurance and timeliness, and propose options for defining and measuring quality in the 
future. Points covered in this chapter include: 
 Activity and outputs from NIHR-funded groups and Cochrane UK. 
 Variability between CRGs and how this is being addressed within Cochrane 
 Challenges in terms of timely delivery of SRs 
 Assessment of performance and quality;  measurement of appropriate and 
transparent key outcome metrics 
Outputs 
Publication of reviews by NIHR-funded Cochrane Review Groups 
Analysis of output by NIHR-funded CRGs cannot solely be judged on number of reviews and 
protocols, as the size of topics and scope of work varies between CRGs. The number of 'empty' 
reviews, those with no included studies, must be considered; alongside broad reviews that 
'lump' together multiple interventions on a topic, and more specific reviews that 'split' down 
into much narrower questions. Consequently, output of CRGs can be assessed using measures 
of clinical relevance and general workload. Much of the information presented below has 
been drawn from comprehensive analysis undertaken by the Cochrane Editorial Unit to 
inform the QQR of UK CRGs undertaken by NIHR in 2013.41 
The table below presents the number of active reviews (reviews that have not been 
withdrawn) registered by each of the NIHR-funded CRGs in Issue 1/12 of the CDSR (January 
2016). 
Table 5: Number of active reviews and protocols by NIHR-funded CRG (up to 26.1.16) 
Cochrane Review Group Active Reviews Active Protocols 
Airways 302 52 
Bone, Joint and Muscle Trauma 118 30 
Cystic Fibrosis and Genetic Diseases 149 29 
Dementia and Cognitive Improvement 125 55 
Common Mental Disorders 154 60 
Ear, Nose and Throat Disorders 101 47 
Epilepsy 83 26 
Effective Practice and Organisation of Care (EPOC) 106 63 
Eyes and Vision 150 56 
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Cochrane Review Group Active Reviews Active Protocols 
Gynaecological Cancer 162 41 
Heart 152 49 
Incontinence 79 16 
Injuries 138 38 
Neuromuscular Disease 121 34 
Oral Health 149 47 
Pain, Palliative and Supportive Care 203 51 
Pregnancy and Childbirth 533 84 
Schizophrenia 198 86 
Skin  77 45 
Tobacco Addiction 73 12 
Wounds 122 54 
Total 3,295 973 
Source: Cochrane Database of Systematic Reviews: Issue 1 of 12, January 2016, (searched 26.1.16)42 
The QQR41 presented another workload indicator: the number of included studies per review. 
The table below shows that new reviews produced by the top five ranked NIHR-funded CRGs 
included between 12.3-21 studies. 
Table 6: Number of included studies per new review for NIHR Funded CRGs. From April 2008 
- March 2013: top 5 CRGs 
Rank NIHR Funded CRG Studies/new review 
1 Heart 21.0 
2 Skin 20.0 
3 Depression, Anxiety and Neurosis (now called 
Common Mental Disorders) 
18.8 
4 Tobacco Addiction 18.6 
5 Schizophrenia 12.3 
Source: Quinquennial review (July 2013)41 
Maintenance and updating workload 
In addition to overall output and included studies, current workload can be analysed 
according to the number of active reviews and active protocols maintained by each CRG 
(reviews and protocols that have not been withdrawn). Table 5 presents the maintenance and 
updating burden by NIHR-funded CRGs, represented as the number of active protocols. 
Withdrawn reviews and protocols were omitted from the analysis. 
Most accessed Cochrane reviews 
Nine of the top 10 most accessed Cochrane reviews of 2014 were produced by NIHR-funded 












1. Gillespie LD, et al. Interventions for preventing falls in older 
people living in the community (2012) CD007146.43 
Yes, BJMT 15,121 
2. Cooney GM, et al. Exercise for depression (2013) CD004366. 
44 
Yes, CMD 13,867 
3. Moore ER, et al. Early skin-to-skin contact for mothers and 
their healthy newborn infants (2012) CD003519.45 
Yes, PCB 13,610 
4. Jefferson T, et al. Neuraminidase inhibitors for preventing 








5. Waters E, et al. Interventions for preventing obesity in 
children (2011) CD001871.47 
Yes, Heart 9,414 
6. Reeves S, et al. Interprofessional education: effects on 
professional practice and healthcare outcomes (update) 
(2013) CD002213.48 
Yes, EPOC 12,461 
7. Zwarenstein M, et al. Interprofessional collaboration: effects 
of practice-based interventions on professional practice and 
healthcare outcomes (2009) CD000072.49 
Yes, EPOC 10,275 
8. Moore ZEH, et al. Risk assessment tools for the prevention 




9. Sandall J, et al. Midwife-led continuity models versus other 
models of care for childbearing women (2015) CD004667.51 
Yes, PCB 9,898 
10. Shepperd S, et al. Discharge planning from hospital to home 
(2013) CD000313.52 
Yes, EPOC 9,828 
Source: Cochrane Collaboration (2015)1, 53 
*"The term ‘accesses’ in the table refers to full text downloads of the PDF and html versions of a 
Cochrane review via Wiley Online Library."1 
'Empty' reviews 
'Empty' reviews refer to SRs that found no studies suitable for inclusion. These reviews 
represent considerable workload in undertaking the review process up to the point of study 
inclusion. Whilst useful in identifying gaps in the research evidence, and need for further 
research, empty reviews may present no conclusions, or conclusions based on excluded 
studies that were not quality assessed. Therefore these reviews may be of limited use to 
clinicians and decision-makers.6, 54, 55 
The number of 'empty' reviews conducted by each CRG varies. In 2013, the Cochrane Editorial 
Unit presented the number of 'empty' new or updated reviews produced by the top five UK-
based* CRGs. 41 
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Of concern are empty reviews with overly restrictive inclusion criteria concerning the types 
of studies, such as only randomised controlled trials, in situations where other types of studies 
addressing the question exist. Empty reviews, in policy terms, are uninformative. While it was 
not possible to fully investigate this issue in the timeframe allowed, examples of an empty 
review produced by an NIHR-funded CRG were identified. A review of vision-screening56 
found no RCTs therefore concluded that there was no evidence available. As a consequence, 
a European organisation57 had to commission a new independent review to include evidence 
from observational studies to provide evidence to inform their decision-making.58, 59 To date, 
this Cochrane review still contains no data and has not been updated since 2009. 
Table 8: Proportion (and total number) of new or updated reviews that are 'empty' (have no 
included studies) 
Rank CRG Empty reviews 
% Total Number 
1 Cystic Fibrosis and Genetic Diseases 34.1% 73 
2 Eyes and Vision 23.0% 26 
3 Neuromuscular Disease 21.6% 29 
4 Developmental, Psychosocial and Learning Problems 
(not NIHR-funded)* 
21.3% 16 
5 Oral Health 19.1% 17 
Source: Hilton (2013)41 *Please note this table included one non-NIHR funded CRG. 
A study conducted in 2010 found that nearly 9% of all reviews published in CDSR had no 
included studies meeting the inclusion criteria.6 The study found that NIHR-funded CRGs 
produced 52% of all reviews on CDSR (2,249/4,320, based on data from Yaffe6) however these 
CRGs also contributed nearly 66% of all empty reviews (248/376, based on data from Yaffe6). 
Table 9: Reviews and Empty Reviews by NIHR-funded CRG (based on data from Yaffe6,  from 
15.8.10) 
Cochrane Review Group Total # of 
Reviews 
# of Empty 
reviews 
% of Empty 
reviews 
Airways 223 26 12 
Bone, Joint and Muscle Trauma 92 3 3 
Cystic Fibrosis and Genetic Diseases 93 25 27 
Dementia and Cognitive Improvement 88 12 14 
Common Mental Disorders (formerly 
Depression, Anxiety and Neurosis) 
111 6 5 
Ear, Nose and Throat Disorders 65 7 11 
Epilepsy 54 6 11 
EPOC 68 5 7 
Eyes and Vision 80 19 22 
Gynaecological Cancer 85 7 8 
Heart 87 4 5 
Incontinence 66 2 3 
Injuries 103 14 14 
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Cochrane Review Group Total # of 
Reviews 
# of Empty 
reviews 
% of Empty 
reviews 
Neuromuscular Disease 83 14 17 
Oral Health 108 18 17 
Pain, Palliative and Supportive Care 134 16 12 
Pregnancy and Childbirth 394 35 9 
Schizophrenia 148 18 12 
Skin  48 3 6 
Tobacco Addiction 53 3 6 
Wounds 66 5 8 
Total for NIHR-funded CRGs 2,249 248 11 
Total on CDSR for all CRGs 4,320 376 9 
 
Figure 5: Reviews and empty reviews for NIHR-funded CRGs and CRGs with other sources of 
funding (based on data from Yaffe6,  from 15.8.10) 
 
These data highlight the underlying issue concerning empty reviews: NIHR-funded CRGs 
undertake a greater percentage of empty reviews that non-NIHR funded CRGs, and each 
empty review represents considerable work up to the point of study exclusion. 
Number of guidelines based on SRs 
Usage and citation of Cochrane reviews in clinical guidelines and guidance acts as an 
important measure of impact. On an ongoing basis, Cochrane UK assess the extent to which 
clinical guidelines by key guidelines developers, are informed by Cochrane SRs.  An 
assessment of this impact measure looked at guidelines by NICE, SIGN and WHO.41 
  




Total # of Reviews # of Empty reviews
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Table 10: Cochrane reviews from UK CRGs that inform NICE guidelines, August 2013: top five 
CRGs 
Rank CRG Number of reviews informing 
NICE guidelines 
1 Pregnancy and Childbirth 158 
2 Schizophrenia 31 
3 Incontinence 28 
4 PaPAS 27 
5 Dementia and Cognitive Improvement 26 
Source: Hilton (2013)41 
Table 11: Number of Cochrane reviews informing NICE, SIGN or WHO guidelines, August 2013: 
top five CRGs 
Rank CRG Number of reviews informing 
NICE, SIGN or WHO guidelines 
1 Pregnancy and Childbirth 202 
2 Schizophrenia 68 
3 Airways 66 
4 Depression, Anxiety and Neurosis 51 
5 Stroke 49 
Source: Hilton (2013)41 
Table 12: Number of NICE, SIGN, or WHO guidelines informed by UK CRG reviews: top five 
CRGs 
Rank CRG Number of guidelines 
informed by reviews 
1 Pregnancy and Childbirth 42 
2 Depression, Anxiety and Neurosis 35 
3 Schizophrenia 20 
4 EPOC 16 
5 Wounds 15 
Source: Hilton (2013)41 
An analysis was carried out to identify the number of NIHR-funded CRG reviews cited in NICE 
and SIGN Guidelines published between 2013 and February 2016. This showed 415 Cochrane 
reviews from 19 of the 21 UK-based NIHR-funded Cochrane Review Groups were cited in 103 
guidelines (74 NICE; 29 SIGN).5 See Table 1 in Appendix 4 for more detailed information. 
Whilst this shows guideline producers identify and cite Cochrane SRs, this does not directly 
demonstrate influence or impact on behalf of Cochrane. 
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Quality of reviews produced by NIHR-funded Cochrane Review Groups 
Cochrane has undertaken the following projects to 
assess variation in quality of review output and 
benchmark methods and processes: 
 Methodological Expectations of Cochrane 
Intervention Reviews (MECIR) audit4 
 Readability study60 
Working on the assumption that the higher quality a 
review is the greater impact and usage it will have, 
the Cochrane Editorial Unit commenced routine 
quality screening for all new Cochrane reviews of 
interventions. Currently diagnostic reviews are 
excluded from this programme. New SRs are 
screened against a subset of MECIR standards.4  
Readability study 
The Cochrane Editorial Unit (CEU) has invested significant time in assessing 'readability' of 
Cochrane review abstracts against a number of key indicators.60 Abstracts of new SRs 
published in October 2011 and 2012 were compared, and for the most part fewer of the more 
recent abstracts failed to meet the basic indicators required, such as reporting the search 
sources and dates, describing the number of included studies and setting out the review 
objectives as a PICO question. Areas of weakness identified in more of the 2012 reviews 
included failing to report risk of bias, failing to describe harms and not giving absolute data 
by comparison group. As a consequence of this readability audit, the CEU made the 
statement, "Transparency is the best arbiter of quality". The CEU further recommended that 
based on the findings of the Risk of Bias (RoB) audit, integration of the Methodological 
Expectations of Cochrane Intervention Reviews (MECIR) standards should be supported with 
training materials and greater prominence of MECIR and Cochrane Handbook advice in 
RevMan.60  The Methodological Expectations of Cochrane Intervention Reviews (MECIR) are 
methodological standards developed by Cochrane, to which all Cochrane Protocols, SRs, and 
SR updates are required to meet. The MECIR standards cover both the conduct and reporting 
of Cochrane SRs. As well as clearly setting out the best practice methods expected to be 
followed within Cochrane, MECIR also offers external readers a transparent guide to the 
requirements for Cochrane reviews.61 
MECIR evaluation 
The following year after making those recommendations, the Cochrane Editorial Unit 
undertook a pre-publication quality assessment and assurance project, to appraise reviews 
by NIHR-funded CRGs prior to publication in CDSR. The CEU's team of editors screened 411 
SRs between September 2013 and September 2015 to see how well the reviews conformed 
the standards required, the Methodological Expectations of Cochrane Intervention Reviews 
(MECIR).19 Reviews were classified into three groups: 
Although this exercise has 
provided invaluable insight into 
the CRGs who perform well 
consistently producing high 
quality reviews,1 the Committee 
notes a lack of transparency in 
disseminating the findings of 
these exercises. It remains 
unclear what remedial action was 
put in place to support those 
CRGs performing less favourably. 
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 Triaged: no or very minor amendments required 
 Minor amendments 
 Major amendments 
Where amendments were required, further action involved referral to an editor from the CEU 
quality team, and additional work was required to ensure SRs were revised to a sufficient 
standard. 
Figure 6: Stage of pre-publication process for NIHR-funded reviews submitted to the MECIR 
screening process 
 
Source: Cochrane Collaboration (2015)4 
The majority of reviews (97%, n=398) submitted for MECIR screening had been signed off in 
the editorial workflow, prior to copy-editing. These reviews were considered the best 
indicator of average quality prior to publication. Thirteen SRs (3%) were referred for screening 
because the CRGs had issues with the way the reviews were being conducted, or because 
there were particular concerns about how the review might be judged if it addressed a 




Signed off in editorial
workflow
Referred due to concerns




Figure 7: Screening classification of reviews by NIHR-funded CRGs (n=398) 
 
Source: Cochrane Collaboration (2015)4 
According to the Cochrane Editorial Unit Quality report (2015): "Minor amendments were 
defined as: where reviews have been assigned to an editor from the quality team in the CEU. 
Typically, these reports include more detailed comments on the abstract, PLS, Summary of 
Findings tables, and main conclusions. All the items picked up here are easily fixed, but the 
reports can vary in length from 3 pages to 6 or 7 in extreme cases. The vast majority of the 
issues identified relate to inconsistencies of interpretation or clarification of how methods 
were implemented. These reports point to issues that are fixable with edits to the text or 
revisions to the GRADE assessments".4 
The Committee wondered to what extent 3-7 pages can still be considered “minor” but as a 
whole, the overall results of the screening project were positive.  Ninety-five percent of all 
assessed NIHR-funded SRs required no or minor amendments. Halfway through the MECIR 
screening project, the CEU quality team excluded reviews from the following CRGs from pre-
publication screening, having decided their SRs were consistently high quality: 
 Airways 
 Bone, Joint & Muscle Trauma 
 Developmental, Psychosocial & Learning Disorders (not in receipt of NIHR-funding) 
 ENT 
 EPOC 
 Eyes & Vision 
 Infectious Diseases (not in receipt of NIHR-funding) 
 Oral Health 










During 2015, two further CRGs were exempted from screening, as their reviews were 
considered to have consistently reached a sufficient standard: 
 Common Mental Disorders 
 Peripheral Vascular Disorders (now Vascular, not in receipt of NIHR-funding) 
The number of SRs screened for each NIHR-funded CRG varied considerably (3-40 SRs). The 
results of the MECIR screening project showed variability between NIHR-funded CRGs. 
Classification of reviews requiring major amendments (0-3 SRs), minor amendments (2-28 
SRs) and triaged (0-14 SRs) varied between the assessed CRGs. The results presented in the 
CEU MECIR report4 showed that for all but one NIHR-funded CRG, the proportion of assessed 
reviews requiring revision (whether minor or major amendments) was greater than those 
requiring no change (triaged). Considering the majority of assessed reviews (97%) had already 
progressed through the editorial workflow process, this raises concerns about how thorough 
the editorial checks and processes are to ensure SRs are robust and error-free. 
Figure 8: Classification of pre-publication screening reports by NIHR-funded CRGs4 
CONFIDENTIAL CONTENT FROM COCHRANE – MADE AVAILABLE TO NIHR 
Source: Cochrane Collaboration (2015)4 
The MECIR screening project appraised a subset of SRs against specific MECIR requirements, 
and categorised the proportion of reviews fulfilling these criteria (Y), partially fulfilling criteria 
(P), failing to fulfil criteria (N), or presenting insufficient information to allow formulation of a 
clear judgement (U). These assessments were presented for two time periods (August 2013 
and August 2014). Of 56 SRs included in the original audit, 28 were published by 15 NIHR-
funded CRGs over the two assessment months. 
Areas of concern existed in key items relating to planned protocol methods, which included 
search methods, subgroup analyses, inclusion criteria and deviations from the protocols. The 
proportion of reviews assessed as being fully or partially compliant with all the audit items 
was higher in 2014 than in 2013. The latter cohort of reviews showed improvements in the 
implementation of GRADE, including summary of findings (SoF) tables. These reviews were 
also assessed as being more internally consistent (MECIR standards for conduct).19 However, 
there was a lack of transparency in the reporting of the MECIR subset assessment, and only 
limited data were presented on the findings for a few select domains. The Committee noticed 
the lack of openness in reporting how well each NIHR-funded CRG performed on all the MECIR 
measures. 
The MECIR project highlighted issues of variability in the way that reviews were conducted by 
NIHR-funded CRGs and supported Yaffe's observations about empty reviews with no included 
studies.6 The number of included studies in reviews assessed between 2013-2014 ranged 
between 0-181 studies.4 Variation also existed in the way reviews were reported; summary 




In addition to producing an internal report on the timeliness and quality of assessed reviews 
by NIHR-funded CRGs,4 the CEU has also produced a table of common errors and good 
practice that is publicly available.62 
Concordance between Cochrane and non-Cochrane meta-analyses 
To assess the concordance between Cochrane versus non-Cochrane reviews Useem and 
colleagues63 conducted a matched pair analysis, comparing pairs of meta-analyses in 
cardiovascular disease that had examined the same set of interventions and outcomes. Their 
objectives included to contrast the two literatures in terms of sample size, numbers of 
included subjects, date of publication, and the degree to which the studies included in each 
member of the pair overlapped. Furthermore, they compared the magnitude of effect sizes 
and shifts in the confidence intervals that would lead to differences in a reader’s 
interpretation of the results; and differences in terms of summary effect size and statistical 
precision. Finally, they assessed how frequently meta-analyses were cited as a function of 
whether and how the results between each matched pair differed. 
Forty matched pairs of reviews were analysed. The two sets were similar in terms of which 
was first to publication, how many studies were included, and average sample sizes. The 
paired reviews included a total of 344 individual clinical trials: 111 (32.3%) studies were 
included only in a Cochrane review, 104 (30.2%) only in a non-Cochrane review, and 129 
(37.5%) in both. Overall, 37.5% of pairs had discrepant results. Non-Cochrane reviews 
reported significantly higher effect sizes and lower precision than their matched Cochrane 
reviews. Reviews reporting an effect size at least two-fold greater than their matched pair 
were cited more frequently.63 
Comparative Risk of Bias (RoB) analysis of Cochrane and non-Cochrane reviews 
An analysis of RoB in Cochrane and non-Cochrane reviews was undertaken to assess the 
methodological quality using a dataset compiled at Kleijnen Systematic Reviews Ltd. Risk of 
bias was assessed using the ROBIS tool. 18 This tool consists of four domains:  
1. Study eligibility criteria 
2. Identification and selection of studies 
3. Data collection and study appraisal 
4. Synthesis and findings.  
A bibliometric analysis was undertaken and is reported in Appendix 3. The internal version of 
KSR Evidence,23 containing in-process and completed assessments, was analysed to look at 
comparative publication rates of reviews published by Cochrane and those conducted by all 
other review producers (non-Cochrane reviews) on the topics of pain and lung disease. 
Reviews classified as "non-Cochrane SRs" are a large group made up of work undertaken by 
all other SR producers; these may include specific organisational subsets, for example those 
in the NIHR TAR programme. 
Further analysis of the three levels of RoB summary was also conducted for completed 
appraisals only. It is important to note that assessment of RoB relates to assessment of 
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methodological quality of each review based on reported methods. The summaries of overall 
RoB were graded as: 
 Low risk of bias 
 High risk of bias 
 Unclear risk of bias 
Figure 9: Risk of Bias (RoB) appraisals for SRs on the combined topics of pain and lung disease 
(2010-2015) 
 
Data were not available to conduct a RoB assessment by NIHR-funded CRGs, however it was 
possible to look at overall RoB assessment for Cochrane and non-Cochrane SRs published on 
the topic of pain, which may be representative of the work of the NIHR-funded CRG, PaPAS. 
Figure 10 presents these data, and shows that Cochrane SRs have a much lower percentage 
of SRs rated as high RoB (10%), when compared to non-Cochrane reviews (80%). For SRs on 
the topic of lung disease, the rate of Cochrane reviews rated at high RoB was even lower (7%), 
compared to non-Cochrane SRs (89%).  
When both topics are considered together (Figure 9), it is reassuring to note that 88% of 
Cochrane reviews are rated to have a low RoB, compared to only 12% of non-Cochrane SRs. 
The finding that 8% of Cochrane reviews (both topics combined) were assessed at high risk of 
bias was in line with the findings of the CEU's MECIR Screening Project, which found 5% of 
NIHR-funded SRs assessed required major amendments.4 
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Figure 10: Risk of Bias (RoB) appraisals for SRs on the topic of pain (2010-2015) 
 
Figure 11: Risk of Bias (RoB) appraisals for SRs on the topic of lung disease (2010-2015) 
 
Impact factors 
Another measurable comparative metric of impact relates to citation usage of publications. 
The most commonly used journal-level citation impact measure is Impact Factor (IF),64 
however there are other impact measures, such as H-index (at author-level) and Altmetrics 
(based on article-level usage and social media activity).  
The CDSR IF for 2014 was calculated as 6.03565 with the five year IF impact factor of 6.539.66 
The CDSR IF of 6.03565 can be interpreted as a review published in the CDSR in 2012 or 2013 
being cited, on average, 6.035 times during 2014. CDSR was ranked 13th out of 153 journals 
in the "Medicine, General and Internal" category, identified by Thomson Reuters.67 This 
placed CDSR in the top 5% of all titles listed in the Journal Citation Report.67 The IF of CDSR 
between 2007-2014 is presented in Figure 1 of Appendix 5. 
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The latest 2014 data are presented in the figure below, and show that Wiley "IF" ranging from 
2.308 to 19.667 for NIHR-funded CRGs; with an average Wiley "IF" of 6.99.68 During 2014 all 
NIHR-funded groups achieved an impact factor that exceeded their five year average score.1 
It is possible that a CRG’s IF may be driven by a single highly-cited review. More information 
on the Wiley calculated "Impact Factor" is presented in Appendix 5.   
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Figure 12: Wiley "Impact Factor" for each UK CRG (i.e. number of cites to reviews published in 2012-2013, divided by the number of reviews 
published in 2012-2013) 
 








































































































































































































CDSR 2014 Impact Factor = 6.035
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UK-based CRGs in receipt of NIHR funding are well-represented in the top 10 most cited SRs 
of 2014, making up 70% of CRGs.67 The most cited SR43 was produced by the Bone, Joint and 
Muscle Trauma CRG, funded by the NIHR. The SR was also included in the value of investment 
analysis included in Chapter 4 of this report. 
Activities 
Activity of NIHR-funded CRGs1 
On an annual basis, an analysis of annual reports produced by all NIHR-funded CRGs is 
conducted and presented to the NIHR Systematic Reviews Programme Advisory Group 
(SRPAG).1 The analysis highlighted several key achievements and activities for 2014.1 
Infrastructure grants 
Infrastructure grants contribute to costs of the editorial bases of all 21 CRGs discussed in this 
report (funding in place from 1 April 2015).1 During 2014, 65% of the 20 CRGs receiving NIHR 
infrastructure funding were within £5,000 of their budgets. Of these, five groups spent 100% 
of their budget, 12 CRGs reported an overspend (ranging from £99 to £29,000) and eight CRGs 
reported an underspend (ranging from £430 to £33,000).1 
Updating 
As part of the infrastructure 
review process, information 
was collated for each CRG on 
whether their reviews were in 
need of updating. 
 
 
















Airways  49 73% 18 27% 
Bone, Joint and Muscle Trauma  36 51% 35 49% 
Cystic Fibrosis and Genetic Disorders  16 36% 28 64% 
Dementia and Cognitive Improvement  35 55% 29 45% 
Common Mental Disorders 45 49% 47 51% 
ENT  2 3% 70 97% 
Epilepsy  1 3% 39 98% 
Eyes and Vision  21 32% 45 68% 
Gynaecological, Neuro-oncology and Orphan 
Cancers  
12 48% 13 52% 
It is apparent that CRGs face challenges in review capacity 
to deal with such numbers of reviews assessed as in need 
of updating. During the 2014 assessment process, 1,250 
reviews were assessed as requiring an update, which were 



















Heart  6 8% 74 93% 
Incontinence  2 7% 26 93% 
Injuries  6 6% 91 94% 
Neuromuscular Disease  12 15% 70 85% 
Oral Health  48 48% 51 52% 
PaPAS 63 47% 70 53% 
Pregnancy and Childbirth  30 9% 312 91% 
Schizophrenia  19 13% 125 87% 
Skin  10 16% 52 84% 
Tobacco Addiction  19 40% 29 60% 
Wounds  4 13% 26 87% 
Source: NIHR Evaluation Trials and Studies Coordinating Centre (n.d.)1* Data from 2014 Infrastructure 
funding summary,1 therefore EPOC Group is not included. 
Further information on Cochrane's criteria for considering where an update is required can 




Editorial support and managerial 
processes 
Each CRG has an editorial team who 
provide advice and support to 
reviewers and authors. Within a CRG, 
the editorial team help prospective 
authors to select and refine their review 
questions, develop and write protocols, 
and act in an advisory capacity 
throughout the review process. Many 
authors highly value this support and 
undoubtedly such support is one of the 
main reasons why Cochrane has built up 
its reputation of producing high quality 
reviews. The CRG editorial team is 
ultimately responsible for the decision 
to publish each protocol and review 
within their group's module, and 
therefore adopts a supervisory role to 
ensure the review is conducted 
according the Cochrane Handbook 
methods69 and that the review meets 
MECIR requirements19, 70 both for the 
conduct and reporting of the complete 
review. Methodological rigour is 
assessed through peer review, audit 
and other managerial quality assurance processes. Access to statistical expertise and support 
from the CRG's trial search co-ordinator or information specialist should also be available. 
CRGs report working towards reducing delays and time manuscripts spend in the editorial 
process; the Injuries CRG have made progress here in their transition towards rapid review 
production. On average a manuscript spends 5.7 months in their editorial process.1 
The Cochrane Editorial Unit assessed the time taken by 49 CRGs from receipt of title 
applications, to registration of titles, publications of protocols and reviews. Only CRGs using 
the workflow system were included, and workflows completed by 26.12.14 were included in 
the analysis (1,130 reviews and 1,472 protocols). The results of the analysis showed variation 
between CRGs for all stages of the review production process.  
The results presented below were not restricted to NIHR-funded CRGs; results were 
anonymised and sorted by the total of the two medians (for protocol and review development 
workflows). These results show that for over half the review groups, the median time for the 
review to be in the hands of the editorial base was more than a year, and for the majority of 
Experiences of authors   
Although many authors receive excellent support 
from the CRGs, the Committee has also received 
several anecdotal submissions of negative 
encounters review authors have experienced with 
poor support from CRG editorial teams. Reports 
received include excessive delays in receiving 
editorial feedback on submitted protocols; one 
group of authors were told to expect feedback no 
sooner than four months after submission. Other 
reports mentioned occurrences of inappropriate 
rigidity concerning inclusion of observational 
studies in circumstances where non-randomised 
evidence would be entirely appropriate to the 
review's scope. This has also been supported by 
evidence from stakeholder interviews.2 
Where review authors voluntarily give of their 
time to undertake review, frequently on top of 
existing professional and clinical "day jobs", a 
more supportive and interactive model of editorial 
support might encourage their continued 
engagement with Cochrane, and future 
involvement in review production. 
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groups, the median time for protocol and review combined to be in the editorial base hands 
was more than 18 months. 
Figure 13: Protocol and review development workflows: time spend at editorial base (days; 
median) for those CRGs that use workflows (sorted by time at base) 
 
Source: Cochrane Collaboration (2015)71 
Several CRGs have expanded their review capacity and reach by establishing satellite groups; 
seven of the UK-based CRGs have done so already.1 The Common Mental Disorders CRG 
(previously known as the Depression, Anxiety and Neurosis CRG) reported a new Suicide and 
Self Harm satellite based at the College of Medicine at Swansea University (funded by 
NISCHR).1 Three NIHR-funded CRGs have established two satellites: the Eyes and Vision CRG 
have a DTA-focused group in Italy and a ‘mini-CRG’ in the US. The Schizophrenia Group have 
satellites in China and India, and the Pregnancy Group has satellites in Australia and Japan.1 
The Skin Group have one established satellite in France and are hoping to set up another in 
the US in the future.1 Although not classified as a satellite, the Wounds Group is supporting a 
group in Queensland to undertake reviews of high priority to both the UK NHS and the 
Australian health system.1 As well as helping to build and expand review capacity, share 
resources and workload and raise a CRG's profile, satellites can also be instrumental in the 
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dissemination of SRs and outcomes. The Heart Group reported their satellite assisted in 
increasing the reach and impact of the CRG's research.1 
Workshops and training 
Training plays an important role in developing and maintaining SR expertise and capacity 
building. 
Cochrane UK employs a small core team who are supported by a wider network of training 
faculty and partner organisations.72 This allows Cochrane UK to offer a flexible approach to 
specific learning needs, but drawing on a wider range of skills and expertise. A range of 
training programmes are provided to meet the learning needs of those preparing SRs, as well 
as support for dissemination activities.72 
In addition to review author training, examples of tailored training activities aimed at health 
professionals, undertaken and supported by Cochrane UK include:72 
 NIHR Academic Clinical Fellows (ACF); 
 Workshops in partnership with the Critical Appraisal Skills Programme (CASP), in 
London, Oxford, Birmingham, Glasgow and Plymouth; 
 Cochrane Fellowships, including the Oxford Deanery Cochrane Fellowship; 
 Medical Trainees Project; 
 Social media interaction via #WeCATS and Tweet Chats; and  
 other forms of ad hoc training. 
Training provided and received by staff at NIHR-funded CRG editorial bases is assessed on an 
annual basis and reported to the NIHR SRPAG.1 
Training given by staff at CRG editorial bases included protocol development, meta-analysis, 
Cochrane and advanced methodology, RevMan, and search strategy workshops. This training 
was delivered in the UK and internationally. Several CRGs also offered to contribute to SR and 
critical training in the UK and internationally, as well as providing one-to-one author support 
and teaching medical students in the UK.1 Training activities by CRGs are mixed. Both the 
Epilepsy and Neuromuscular CRGs reported that no formal training had been provided by the 
editorial base during 2013-2014, although new author training continued and existing authors 
received support whenever methodological and software changes occurred. The 
Gynaecological CRG conducted a health economics workshop for attendees from UK CRGs, as 
well as methodologists, authors and co-ordinating editors.1 Most of the training is rather basic 
and there is increasing demand for higher level training in editing skills and higher level author 
skills. 
Specialised registers maintained by NIHR-funded CRGs 
The editorial base of each CRG is tasked with developing and maintaining a specialised register 
of RCTs relevant to the group's particular topic or health problem of interest, as an essential 
core function.73 Often a CRG's trial search co-ordinator will facilitate the search process for 
compiling and updating the specialised register, namely by developing and running complex 
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search strategies to retrieve relevant RCTs on the topics and conditions outlined in the CRG's 
inclusion criteria. Records are also identified from other sources, for example, hand searching 
of journals and conference proceedings, and checking of reference lists and other external 
trial registers. Typically CRG specialised registers are restricted to RCTs, however some groups 
are beginning to consider inclusion of other relevant study designs. The EPOC Group has made 
progress in this area. On a quarterly basis, data from CRG specialised registers are aggregated 
to form with Cochrane Central Register of Controlled Trials (CENTRAL),42 available as part of 
the Cochrane Library.74 
The number of reports held in a CRG's specialised register could be used as an indicator of 
workload and output, however this approach has certain limitations.41 Different CRGs 
compile, maintain and use their specialised registers in different ways, which may impair 
comparability. Between CRGs there are variations in their group's scope, some may be narrow 
and quite specialised (e.g. Cystic Fibrosis and Genetic Diseases), whereas others may be broad 
encompassing a wider range of topics (e.g. Pregnancy and Childbirth). For these reasons, 
direct comparison of specialised register content and output may not be a true measure of 
CRG activity. Nevertheless, the size of a CRG's register may provide some indication of the 
research activity within each CRG's scope.41 
Considerable NIHR-funded CRG activity goes into compilation and maintenance of specialised 
registers. The UK CRG's Quinquennial Review Report41 rated the PaPAS CRG register as the 
largest in the UK, containing the most studies (45,025 studies in 2013; see Table 1, Appendix 
6).41 Rankings were also presented to identify the top five UK CRGs, calculated as the ratio of 
number of active reviews per 1,000 register records.41 The Gynaecological Cancer CRG was 
ranked as the top NIHR-funded CRG with 30.04 reviews per 1,000 register entries (see Table 
2, Appendix 6).41 
For more information on the number of studies in NIHR-funded CRG specialised registers, 






Performance of NIHR-funded CRGS and Cochrane UK: Main points 
 Cochrane has had a substantial output  
 Cochrane needs to articulate and define its core business and products better; 
users value timely, high quality, full systematic reviews that are relevant to NHS 
decision making. Relevance of reviews, and coverage of topics remains an issue 
 Nine of the top 10 most accessed Cochrane reviews of 2014 were produced by 
NIHR-funded CRGs. 
 Considerable variability in procedures, customer service, and quality exists 
between reviews and CRGs, however this is not well addressed 
 Editorial groups are often slow with turn arounds to authors 
 Quality is a critical point, which requires openness and transparency. 
 Quality of Cochrane reviews is good relative to non-Cochrane reviews, a small 
proportion of Cochrane reviews are not good quality 
 The relationship between CRG performance and volume of specialised register 
activity remains unclear 
 Groups are not able to maintain updating of all reviews, and some important 
reviews remain out of date  
 Cochrane needs to more widely address the scope of evidence being used; 
encouraging more focus on sources of data other than RCTs, such as data from 






CHAPTER 3 - MEETING KEY CLINICAL AND POLICY QUESTIONS IN THE 
NHS 
Overview 
This chapter will discuss how much impact NIHR-funded CRG reviews and Cochrane UK 
has had on health care and policy-making, and how well this work aligns with the aims 
and priorities of the NHS. Impact will be discussed in terms of: 
 Policy and NHS Planning  
 Methodology development and progression for systematic reviews in Cochrane 
(better reviews, timely etc.) 
 Research 
 Health outcomes 
Current NHS plans 
The purpose of Cochrane as a whole is to prepare, maintain and promote SRs to inform 
healthcare decisions,69 and by doing so, improving people's health and wellbeing. Within the 
UK, NHS England set out its plan for the future of the NHS in the document the "NHS Five Year 
Forward View".75 Developed in partnership with health and care organisations such as the 
Care Quality Commission, Public Health England and NHS Improvement (previously Monitor 
and National Trust Development Authority), the Five Year Forward View strategy proposes 
new models of integrated health and social care intended to close "widening gaps in the 
health of the population, quality of care and the funding of services."75 
For Cochrane UK (i.e. the Cochrane Centre in Oxford) to meet its aim of informing healthcare 
decision-making, it needs to align its priorities, actions and output with those of NHS England, 
which are summarised and presented in Appendix 7. Cochrane UK functions as the "front 
door" contact for relationship building. A key area for expansion is to function as an interface 
between review groups and policy/decision makers. Cochrane UK should provide assistance 
in terms of facilitating, enabling and delivering priority reviews. Mechanisms should be put in 
place to deal with any delays. 
Alongside the Five Year Forward View's vision75 for shared care sits the NHS England Research 
and Development (R&D) Strategy, currently in a draft form following an extensive 
consultation process.76 The Research and Development Strategy draws a clear process for 
promoting and building a culture within NHS England that values and promotes research and 
innovation. It notes the importance of engaging with partner organisations and building on 
existing relations with the NIHR, Health Education Institutes (HEIs), Public Health England, 
Local Authorities and other stakeholders. Many of the aims of the R&D Strategy sit within the 
potential strengths of Cochrane, including promoting uptake of research skills, training 
providers, collaboration between individuals and organisations, and engagement with 
patients and the public. 
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Better reviews: relevant, timely and high quality 
Although Cochrane reviews in the UK represented very good value, there is reliance on 
volunteers and support from other funders, and between-CRG variation in outputs and 
activity.  Cochrane must address the need for better reviews that are relevant, timely and of 
high methodological quality, to support decision-makers, guidelines writers, patients, 
clinicians and managers. The specific issues Cochrane must deal with include: 
a. Patient/public involvement for review scoping and context   
b. Collaboration with NICE 
c. Prioritise to topics of greatest importance 
d. Keep more reviews up-to-date 
e. Prepare reviews more rapidly 
f. Use best available evidence, beyond RCTs 
What impact has Cochrane had in meeting clinical and policy issues in the NHS? 
Impact of Cochrane SRs should not be solely measured in citations within guidelines and 
guidance.1 For any review to be considered having impact, it should result in the following 
outcomes: 
a) Results in a clear research recommendation; leading to further commissioned 
research  
b) Results in a change in practice or behaviour; measurable impact on NHS healthcare  
c) Contributes to the research portfolio of evidence; which in turn may result in either of 
the above  
Policies 
One method of assessing Cochrane impact on UK policy-making and practice involves 
quantifying the impact SRs have on NICE Quality Standards (NICE QS).41 NICE defines their 
quality standards as:77 
"... concise sets of prioritised statements designed to drive measurable quality improvements 
within a particular area of health or care. They are derived from the best available evidence 
such as NICE guidance and other evidence sources accredited by NICE. They are developed 
independently by NICE, in collaboration with health and social care professionals, their 
partners and service users." 
It should be noted that NIHR-funded CRGs are not directly comparable due to the intrinsic 
differences between groups; i.e. some CRGs relate to a broad topic area, whereas other might 
focus on a single condition. When examining CRG impact on NICE QS, some CRGs might be 
restricted to one or two standards (e.g. the Cystic Fibrosis and Genetic Diseases Group), 
whereas others may relate to many standards (e.g. the Heart Group). Consideration of other 
CRGs, such as the Wounds or the EPOC Groups, required a degree of subjectivity to match the 
CRG to the published NICE QS.41 
Within the top five ranked UK-based CRGs for this assessment, four were in receipt of NIHR-
funding and one was not (based in Ireland). 
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Table 14: NICE quality standards and how they relate to UK CRGs, as assessed by Hilton and 
Tovey for their report: top 5 CRGs 
Rank CRG Relevant NICE Quality Standards 
(QS) 
1 Pregnancy & Childbirth 14 
2 Heart 12 
3 Depression, Anxiety and Neurosis (now called 
Common Mental Disorders) 
11 
4 Psychosocial (not NIHR-funded)* 11 
5 Gynaecological Cancer 7 
Source: Quinquennial review (July 2013)41 *Please note this table included one non-NIHR funded CRG. 
An important and high impact NICE guidance document, about preventing falls and assessing 
risk in older people, was published in 201378 The guidance was informed by an SR published 
by the NIHR-funded BJMT CRG, which was last updated in 2012.43 Evidence surveillance 
undertaken within NICE has identified a minimum of 35 new trials potentially eligible for 
inclusion in an update of the Gillespie SR, however an update of this review is not planned to 
be completed until 2017. The review in question was the most cited SR on CDSR during 2014,67 
Given the relevance to the NHS, resource use, health impact and research funding, this SR 
should be prioritised for an expedited update, not least to ensure currency of NICE Guidance. 
NIHR-funded CRGs who produced high impact reviews during 2013 which led to further 
primary research, included the Heart, Incontinence, Oral Health and Wounds groups 1 
Alderson and Tan examined the extent of citation of Cochrane reviews in NICE guidelines. 79 
There were 731 citations of Cochrane reviews in the 106 guidelines, ranging from no citations 
to 44 citations, with a mean of 6.90 (standard deviation 9.23). Some Cochrane reviews were 
cited more than once in different guidelines; therefore, the figures do not represent the 
number of Cochrane reviews cited. Although the data show an impressive level of use of 
Cochrane reviews in NICE clinical guidelines, there is scope for better use of the knowledge 
contained in CRGs when NICE draws up the scope for guidelines, and to encourage more 
involvement from Cochrane review authors on NICE guideline development groups. Cochrane 
and NICE could do more to ensure that Cochrane reviews and guideline questions are better 
aligned, work harder at sharing knowledge from Cochrane reviews and guidelines in 
development, and try to speed up the editorial process of turning relevant Cochrane protocols 
into Cochrane reviews, or updates of Cochrane reviews, so that they can be considered for a 
clinical guideline. 
Reviews that change practice and change or save lives 
Relevance to NHS 
An evaluation to rate selected reviews completed by NIHR-funded CRGs was conducted by 
the NIHR Evaluation Trials and Studies Co-ordinating Centre (NETSCC).80 The purpose of this 
exercise was to determine how relevant to the NHS a sample of Cochrane reviews was judged 
to be by clinicians, policy-makers and members of the public. A cross-section of raters from 
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the NDC 'College of Raters' were asked to explore where a selection of reviews from each of 
the NIHR-funded CRGs were considered of relevance to the NHS. Review titles were selected 
from the CRG 2015 annual reports, which detailed all reviews published in 2014 against their 
infrastructure grant. This referred to reviews not funded via any other funding scheme or 
grant. The first three reviews reported from each CRG were selected for relevancy rating. No 
further selection criteria were followed. 
Raters were asked to answer Yes, No or Unclear; and were given the following definition of 
relevance to follow: 
"By relevance to the NHS we mean, in your opinion, the research is likely to be of use to (all 
or some of) clinicians, patients, commissioners and policy makers within the NHS setting" 
Two users were approached from each of the following categories of raters within the NDC 
College of Raters: 
 Public rater 
 GP/AHP rater (GP, nurse, allied health professional, specialist practitioner) 
 Commissioning rater (commissioner, allied health policy, manager) 
Despite aiming to include two individuals from each of these categories, some invitations 
received no response. As such not all reviews received a full six relevance ratings. 
Once rating was completed, each review was classified according to the following opinion-
based relevancy coding, so that an overall rating could be achieved using a 'traffic light' 
system, presented below: 
Table 15: NETSCC Relevancy coding, number and percentage reviews ranked by judgement of 
relevance 
Key Relevancy code Number of assessed 
reviews 
% of assessed reviews 
 Relevant, no more than one No or 
Unclear rating 
25 42 
 More than one No or Unclear rating 34 57 
 All No or Unclear ratings 1 1 
 Total 60 100% 
Source: NETSCC (2016)80 
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Of the 60 SRs assessed, only one was rated as 'not relevant' 
to the NHS (all responses given as "no" or "unclear"). Forty-
two percent of assessed Cochrane SRs were graded as 
relevant, and 57% of assessed SRs were classified as having 
no or unclear relevance by more than one respondent. As 
previously detailed the number of ratings received differs 
for each review assessed, which skews the overall results. 
The raw data is included in Appendix 8. 
This was a rapid exercise conducted to inform the NIHR 
evaluation. As such, there are some limitations due to the 
rapid timeline for completion of the rating process, 
including arbitrary selection of systematic reviews from 
each CRG, which potentially may not be representative of 
each CRG's work programme, together with missing data 
from a lower than expected response rate. Despite these 
considerations, nearly all the assessments rated the SRs as 
green or yellow for relevance, and only one SR was rated as 
not relevant.  
A benefit of an organisation driven by individual reviewers and clinicians, rather than by 
funding bodies, is the focus on both patient- and clinician-relevant topics. A hypothetical 
scenario to illustrate this might involve Cochrane volunteers undertaking a review of footcare 
for diabetics in the community. Topic prioritisation at a top-down commissioner-level may 
not identify this as a priority topic, however patients and frontline healthcare professionals 
would be more aware of the positive impact such a service can have on diabetes-related 
complications and quality of life.  
Engaging health care professionals and health care organisations has additional benefits; 
participation of clinicians in health research has been linked to improvements in the delivery 
of health care and patient outcomes.81 Successful engagement appears to work at two levels; 
firstly at an organisational level, and secondly by way of close working between researchers 
and clinicians.81 
Addressing burden of disease 
In order to assess UK CRGs whose scope matched the priority areas for clinicians, decision-
makers, patients and public, the CEU undertook analysis of topics covered by UK CRGs, to see 
how they performed against two measures of disease burden.41 The performance measures 
selected to assess clinical priority were: 
 Years of life lost to premature mortality (YLL), and 
 Years lived with disability (YLD). 
A key benefit of Cochrane's 
collaborative model of working 
alongside reviewers who are 
also health care professionals 
is that the review authors 
based within the health care 
system gave in-depth and 
acute knowledge of their 
particular topic of interest that 
top-down researchers may not 
be aware of. The 
reviewer/clinician-level 
approach enables insight and 
innovation at this level, 
increasing relevance to the 
NHS and impact on health care. 
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As the analysis included all CRGs based in the UK, the remit was broader than that of this 
report, as CRGs based in the UK but funded by organisations other than NIHR were included, 
such as the Infectious Diseases and Stroke Groups. 
When the top 10 causes of YLLs in the UK for 2010 were ranked against UK CRGs, four of the 
five UK CRGs were funded by NIHR (80%, see Table 16 below). This represented coverage of 
40% of top 10 causes of YLLs. 
Table 16: Top 10 causes of YLLs in the UK in 2010 and how they related to UK, and NIHR-
funded, CRGs 
Mean rank Condition/clinical priority area NIHR Funded CRG 
1.0 Ischaemic heart disease Heart 
2.3 Lung cancer  
2.7 Stroke (Stroke: not funded by NIHR) 
4.4 COPD Airways 
4.6 Lower respiratory tract infections  
6.0 Colorectal cancer  
7.1 Breast cancer  
9.3 Self-harm Depression, Anxiety and Neurosis (now 
called Common Mental Disorders) 
9.3 Cirrhosis  
9.3 Alzheimer's disease Dementia and Cognitive Improvement 
Source: Hilton (2013)41 
Analysis of causes of YLDs in the UK in 2010, indicated that four NIHR-funded CRGs were 
included in the top 10 rankings, and two of those CRGs covered two topics each. This 
represented 60% coverage of the top 10 causes of YLDs, as an indicator of relevance to clinical 
priority areas. 
This analysis failed to indicate what percentage of SRs were not ranked as relevant, and this 
remains an area of uncertainty. 
Table 17: Top 10 causes of YLDs in the UK in 2010 and how they related to UK, and NIHR-
funded, CRGs 
Mean rank Condition/clinical priority area NIHR Funded CRG 
1.0 Low back pain  
3.7 Falls BJMT 
3.8 Major depressive disorder Depression, Anxiety and Neurosis (now 
called Common Mental Disorders) 
3.9 Neck pain  
4.7 Other musculoskeletal disorders  
6.1 Anxiety disorders Depression, Anxiety and Neurosis (now 
called Common Mental Disorders) 
7.1 COPD Airways 
8.5 Drug use disorders  
8.7 Asthma Airways 
8.9 Migraine PaPAS 
Source: Hilton (2013)41 
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Unfortunately information was not available presenting how many NIHR-funded did not 
match to related YLDs. 
Behaviour change: professional/clinical/public 
An assessment into how stakeholders value Cochrane 
SRs3 showed that although policy-makers use the 
reviews to inform clinical guidance in the UK and 
internationally, the reviews are judged to be less 
helpful when they are out of date or the research 
question is too restrictive. Certain Cochrane reviews 
were found to have contributed to identification of 
gaps in the evidence base, and subsequently 
stimulating new research in the area. Bunn et al (2015)3 
identified several impacts and likely impacts of 
Cochrane reviews. Among these, the most well-defined 
were targeting research gaps and health-care policy. 
There was less evidence of a direct impact on clinical 
practice and the organisation and delivery of NHS 
services.  
The Neuromuscular, PaPAS, Injuries and Tobacco Addiction CRGs all produced high impact or 
breakthrough reviews which have a potential for a change in practice.1 A notably influential 
review that impact on guidance was a review on nicotine replacement therapy (NRT).11 The 
review, published by the NIHR-funded Tobacco Addiction CRG, was noted as being cited in 
the NICE Guidance on brief interventions and referral for smoking cessation.82 Furthermore, 
the NRT SR11 was also cited by WHO as high quality evidence of effectiveness, and NRT was 
added it to their list of essential medicine. This SR has been incorporated into international 
guidelines from the US and Australia, and is an excellent example of a high impact SR.10 
NICE developed the Cochrane Quality and Productivity (QP) topics83 to aid the NHS in 
identifying practices that could be stopped or reduced significantly, freeing up funding and/or 
resources without a negative effect on the quality of NHS care. All QP topics are available in 
the public domain,83 and each was derived from a Cochrane SR that has concluded the 
evidence showed a practice to be harmful or ineffective, and that the practice should not be 
used, or that there was insufficient evidence to support widespread adoption of the practice. 
Each QP considers the cost to the NHS, a current estimate of NHS use, levels of productivity 
savings anticipated, any costs to implement the recommended changes, the potential impact 
to the NHS and the likely ease and timeframe of implementation of the recommended 
changes. 
A sample of QPs were assessed, identifying practice changing reviews from over half of the 
NIHR-funded CRGs (13/21 CRGs). A selection of these QPs identified practice changing 
recommendations from recent SRs and are described in Appendix 9. A full list of the NICE QPs, 
together with an illustrative example, are presented in Appendix 10. 
While reviewers and researchers 
should consider how they could 
increase the influence of their 
reviews, impacts such as these 
are difficult to measure.3 The 
Committee feels that more work 
is required into suitable 
methods for impact analysis, 
and in Chapter 6, suggests the 
need for clearer definition and 




Reviews relevant to social care 
Cochrane needs to recognise the importance of social and community care in underpinning 
health. Some CRGs are already undertaking SRs of relevance in these areas.10 One of the key 
challenges faced by Cochrane in the future, is the ageing population and increasing demands 
on health and social care.10 Reassuringly, stakeholders acknowledge that engagement with 
Cochrane to focus on topics, such as multi-morbidity, ageing and long-term conditions, will 
be key in answering these "big questions" faced in the future by the NHS.2  
Culture change: concept of scientific rigour and independence 
Cochrane as a gold standard 
The perception of Cochrane as a gold standard of evidence and SR methodology is wide-
spread, and this was endorsed by many of the stakeholder interviewees. 
The Committee asked NIHR to commission some stakeholder interviews about their views of 
Cochrane.2 Thirty-four interviews were conducted with a range of Cochrane review users and 
producers, many of whom have multiple roles and interests in evidence synthesis and how 
the products of this are used in health care in the UK. The full report is included in Appendix 
11. The following quotes from the report are relevant to the perception of Cochrane as a gold 
standard: 
 "Cochrane was in the vanguard of suggesting that research is not just for researchers 
and has contributed to the wider health and research culture in this regard."2 
Although Cochrane as a whole is seen as a recognisable brand endorsing best evidence, 
concern exists among stakeholders that timeliness and relevance to policymaking is variable. 
 "You have pieces of very well done research that have limited use and interest to policy 
and practice development and/or commissioning".2 
As scope and complexity of reviews increases, stakeholders are increasingly questioning 
Cochrane's flexibility to deal with differing sources of evidence, including observational 
studies. 
Cochrane UK has offered week long training programmes for Academic Clinical Fellows (ACF) 
and provided opportunities for local trainees to participate in a six month full-time placement 
as a 'Cochrane Fellow'. This training placement has been held in high regard and designated 
by the UK Faculty of Public Health as a "National Treasure".84  
Fostering transferrable skills in the NHS is highly valued, however as noted before, negative 
author experiences may discourage reviewers from participating in Cochrane reviews in the 
future.2 
Promote understanding of EBM and systematic reviews among end-users, in particular the 
public 
Cochrane UK has worked to build greater recognition of the need and use of SR evidence, and 
to develop Cochrane's profile as an advocate for evidence-informed healthcare.85 One way to 
achieve this at a grass-roots level is to engage students and future clinicians. The 'Students 4 
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Best Evidence' (S4BE) initiative involves an international network of students with an interest 
in learning about evidence-informed health care, who develop their skills by reviewing online 
resources, and engaging in discussions and student-led tutorials.85 
Cochrane UK encourages engagement with charities, professional bodies and NHS 
organisations. Examples of this work include a weekly list of new and updated review titles to 
patient and consumer charities, e.g. the National Childbirth Trust (NCT), and to membership 
organisations, such as the Association of Medical Research Charities (AMRC). Where possible, 
Cochrane UK works alongside organisations to produce evidence-informed materials and 
publications to support their aims.85 
Cochrane UK has commissioned independent research to inform and improve communication 
and collaboration with NHS organisations involved in policy-making and commissioning. This 
research will aid further development of networks and relationships within the NHS.85 
Despite these efforts, work still needs to be done to promote the value of SRs to the public 
and especially to policy-makers10 and health commissioners, who are interested in having 
dialogue about how to achieve this.2 
Communicating with relevant audiences 
Many of the NIHR-funded CRGs reported that the Cochrane Consumer Network32 acted as a 
link to establish and maintain links with consumers, although the level of consumer 
involvement varied greatly across groups, and was described as being dependent on how 
much of the CRG's overall budget had been allocated to such activity.1 CRGs noted that 
consumers played an important role in identifying and highlighting gaps in research, and 
consumers were increasingly becoming involved in areas such as:1 
 Input to topic prioritisation 
 Impact of treatment on patients 
 Membership of advisory panels 
 Development of plain language summaries 
 Refereeing protocols and reviews 
 Outcomes development 
In reality, there seems to be variable experience in implementing consumer involvement, and 
this should be the focus of the Consumer Network 2020 strategy. 
Open access 
Cochrane is working in partnership with Wiley, and has established a mechanism for open 
access. The strategic plan states all reviews and protocols will be open access by 2020.86 But 
the actual steps to achieve this and whether the financial model will hold remains unclear. As 
a first step towards full open access, all new Cochrane reviews became free to access for all 
readers 12 months after publication, from February 2013.9 On 12 April 2016 a PubMed search 
identified 519 records within the Cochrane Database of Systematic Reviews as available via 
open access. 87 Cochrane has informed the Committee that 2,572 reviews were available as 
open access, as of Q3 2016. Although this transformative initiative will enable freely available 
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Cochrane SRs for all globally, there are concerns regarding possible impact of loss of Cochrane 
Library royalties on the financial stability of Cochrane. Funders and Cochrane (and the 
publisher of the Cochrane Library) need to do work on how to move towards open access to 
increased accessibility to Cochrane Reviews. Transparency in proposed plans is encouraged.10 
Plain language summaries 
Plain language summaries are produced to offer a format easily accessible and 
understandable by patients and the public. Improvements in the format and content of lay 
summaries can be achieved by engaging consumers in the planning, writing and production 
of the summaries.10 
Social media 
Cochrane as a whole has adopted new technologies and social media to engage and 
communicate with a variety of audiences.88 Twitter and blogging have proved useful media 
to reach Cochrane users and commissioners.  
Twitter is being utilised as an easily accessible medium for frequently, daily communications 
aimed at clinical staff. The majority of social media activity is undertaken centrally by CEU and 
Cochrane UK or by CRGs, rather than at an individual review author-level, with many CRGs 
interacting with external review users and stakeholders via Twitter and other web-based 
forms of communication. This communication activity is often facilitated by Cochrane UK, 
who have also offered social media training to further enable successful exploitation of social 
media as a dissemination tool.1 
Furthermore, some CRGs have also been successful in setting up and contributing on a regular 
basis to “Cochrane Corners” within high impact, relevant journals.1 
Many NIHR-funded CRGs, including the Common Mental Disorders Group in particular, 
published SRs which were highly cited or received considerable media attention and social 
media activity.1 
Cochrane UK's twitter campaign includes focussed regular communication about 
commonplace and frequently occurring topics, on trends such as: 
 Evidence for Everyday Midwifery (#EEMidwifery) 
 Evidence for Everyday Nursing (#EENursing) 
In addition to designated threads, Cochrane UK have hosted tweetchats, such as 
@WeNurses89 tweetchat about re-siting cannulae. 
Cochrane as a whole has developed a relationship with Wikipedia, aimed at closer 
engagement between Cochrane and the Wikimed community. Wikipedia represents a well-
known and well-used internet resource, and the partnership allows Cochrane to raise its 
profile, ensure articles are accurate, up-to-date and informed by review evidence. Cochrane 
UK continue to support the Wikipedia project by giving details of new and updated reviews 




The Evidently Cochrane initiative90 features weekly blogs aimed at patients, carers, the 
general public, clinicians, researchers, decision- and policy-makers. Blogs cover findings of 
specific reviews in an accessible news-style format, as well as explaining the reasoning behind 
undertaking reviews to answer uncertainties in health and health care. Evidently Cochrane 
UK has been using a successful format for communication, winning a UK Health Blog Award 
in 2015. 
Two high-impact blogs highlighted important engagement between Cochrane and patients, 
carers and the public. The first resulted from a collaboration between Cochrane UK and a 
carer of a person with Motor Neurone Disease (MND), and was published during MND 
Awareness Month. The blog investigated evidence from Cochrane reviews of MND treatment 
and disease management, within the context of the patient's experiences.85 The second 
impactful blog, written by a young person with cystic fibrosis (CF) linked the work of the NIHR-
funded Cystic Fibrosis and Genetic Diseases CRG, with the real-life experiences of a child living 
with CF. 85 
The next step would be more consistent social media 'conversations' about aspects and 
impact of SRs with Cochrane learning from end users what their interests and experiences are 
with using evidence generally and Cochrane evidence in particular. 
Methodology 
Although NIHR does not fund methods groups, Cochrane as an organisation has acted as a 
key driver of research synthesis methods development and actively promoted adoption of 
many aspects of systematic review methodology. Innovations developed within Cochrane 
have been adopted by reviewers on a global scale. 
Table 18: Methodologies developed within Cochrane and/or facilitated by Cochrane (for 
example, meetings at Cochrane Colloquia) 
 Cochrane tool for assessing risk of bias in randomised trials91 
 Cochrane risk of bias assessment tool: for non-randomised studies of interventions 
(ACROBAT-NRSI)92 
 Cochrane Highly Sensitive Search Strategy (HSSS) for identifying randomised 
controlled trials in Medline93 
 Prediction study Risk Of Bias ASsessment Tool (PROBAST)94 
 Risk of bias in systematic reviews tool (ROBIS)18 
 Indirect and mixed treatment comparisons95 96 
 Network meta-analysis97, 98 96 
 QUADAS-299 
 Transparent reporting of a multivariable prediction model for individual prognosis 
or diagnosis (TRIPOD)100, 101 
 Quality in Prognostic Studies (QUIPS)102 
 Checklist for critical Appraisal and data extraction for systematic Reviews of 
prediction Modelling Studies (CHARMS)103 
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 Screening Embase for RCTS using Crowdsourcing104 
 Methods to identify reports of adverse effects (AE)105-109 
There are areas where reviews are being undertaken by other producers where Cochrane has 
yet to carry out many SRs. These areas include aetiology, diagnostics and prognostics. 
However, Cochrane has helped develop methodologies for conducting diagnostic110 and 
prognostic reviews.111 Cochrane has also carried out considerable work in developing 
methods to systematically investigate adverse events (AE).112 
Personal communication from Stefan Lange at the Institute for Quality and Efficiency in Health 
Care (IQWiG) in Germany indicated that IQWiG highly values Cochrane for their 
methodological contribution and that senior methodological staff from IQWiG specifically 
attend the Cochrane Colloquium for this purpose.113 
Cochrane Methodology Group 
The Cochrane Methodology Group aims to "summarise the empirical basis for decisions about 
methods for systematic reviews and evaluations of healthcare, including preventive, 
diagnostic, therapeutic, rehabilitative and educational interventions".114 The main focus is to 
examine methodological studies that make use of empirical data derived from SRs. The 
Cochrane Methodology Group compiles the Cochrane Methodology Register (CMR) which is 
available as part of the Cochrane Library.42 The Group provide structured abstracts of 
methodological studies and reviews in the annual 'Cochrane Methods' publication,115 which 
acts as a supplement to the CDSR.24 
Cochrane as a benchmark 
For conduct and reporting of SRs 
Many SRs refer to following the principles laid out in both the Cochrane Handbook69 and the 
Centre for Reviews and Dissemination's guidance for undertaking SRs in health care.116 The 
Cochrane Handbook is viewed as the dominant source for SR methods guidance. A pragmatic 
citation search undertaken using Google Scholar117 suggests in excess of 20,000 documents 
cite the Cochrane Handbook.117 
International guidance produced by the US Agency for Healthcare Research and Quality 
(AHRQ),118 the Institute of Medicine for the National Academies of Sciences (IoM)119 and the 
Institute for Quality and Efficiency in Health Care (IQWiG)120 each refer to the Cochrane 
Handbook as the gold standard source. 
Similarly the Cochrane tool for assessment of risk of bias in randomised studies91 has been 
adopted by thousands of review producers. 
Seen as trustworthy 
Cochrane is seen as a trusted source by healthcare professionals, clinicians, guideline 
developers, information producers and infomediaries.2 Cochrane evidence is also valued by 
health commissioners, policy developers, NHS managers and the public, however they find it 
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more challenging to use in a practical sense. Consequently, they value it less than could be 
the case, leaving room for additional improvement.2 
Meeting key clinical and policy issues in the NHS: Main points 
 Impact needs to be assessed in a meaningful way, and Cochrane should be more 
proactive in its planning or anticipation of impact 
 Impact will only happen if prioritisation is done better. Existing processes are helpful 
but the Committee feels these could be more successful if there is a more centralised 
strategy to bring structures together.  
 Cochrane has had substantial collateral impact having influenced methodological 
developments. Looking forward, Cochrane needs to proactively embrace other 
approaches such as incorporating cost-effectiveness information and using the best 
available evidence, which includes observational studies where RCTs are missing. 
 Uncertainties exist surrounding the proportion of NHS vs academic reviewers. The 
opportunity costs of utilising NHS clinicians should be balanced against the benefits of 
embedding research into practice. A research-active clinician is a better clinician for 
improved patient outcomes. 
 A large volume of Cochrane activity does not have an impact, often due to timing. 
Cochrane should be encouraged to consider upcoming guideline questions to identify 
review title priorities. It is essential to get an overall profile of Cochrane impact as a 
whole, rather than focussing on single impactful reviews. 
 For many NHS institutions Cochrane is the first port of call; an important impact 
message 
 To date Cochrane has had an impact on people, methods, policy, research, and health 
outcome. Are CRGs proactive enough to sustain these impacts? Were reviews 









The chapter describes four case studies to evaluate the economic value of Cochrane 
reviews to the UK and the value of increased/faster adoption of healthcare interventions 
in the NHS resulting from the publication of Cochrane reviews, key points include: 
 The value of implementing four healthcare interventions recommended in four 
exemplar Cochrane reviews is estimated by applying the value of implementation 
Value of Investment Model (VOIM) framework described in Fenwick et al.121  
 This framework operates by seeking to assess the value per patient of 
implementing a healthcare intervention. These benefits are scaled up to the 
population level by considering the size of current and future population eligible to 
receive the intervention.  
 Value for money of Cochrane reviews 
 Considerations for Cochrane to incorporate economic evaluations  
 Possible outcomes of implementing Cochrane reviews 
For this chapter, NIHR commissioned work from the University of York, Centre for Reviews 
and Dissemination (CRD) and the Centre for Health Economics (CHE), which aimed to evaluate 
the value of Cochrane reviews to the UK and specifically to evaluate the value of 
increased/faster adoption of healthcare interventions in the NHS resulting from the 
publication of Cochrane reviews. 
York CRD/CHE study 
This study122 has estimated the value of implementing four healthcare interventions 
recommended in four exemplar Cochrane reviews by applying the value of implementation 
Value of Investment Model (VOIM) framework described in Fenwick et al.121 This framework 
operates by seeking to assess the value per patient of implementing a healthcare 
intervention. These benefits are scaled up to the population level by considering the size of 
current and future population eligible to receive the intervention. The full report is in 
Appendix 12. 
Four Cochrane reviews were selected for the analysis. The selection of the four reviews was 
carried out by the committee from a short list of 16 reviews; eight of which were put forward 
by the committee, and eight of which were put forward by the York team. The reviews 
selected were chosen as exemplars because they are considered to have had a major impact 
in either in shaping NICE guidelines or have significant implications in terms of improvements 
in health. However it was difficult to find acceptable examples of impactful Cochrane reviews 
that could be matched to corresponding economic models. 
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The questions to be addressed were as follows: 
1. What is the value, in terms of both health and monetary value, of implementing the 
health care intervention identified as effective in the four Cochrane reviews? 
2. Given plausible values for the degree to which a Cochrane review may influence 
practice what is the value of each of these Cochrane reviews both in terms of 
improved health and economic value? 
3. What factors are likely to influence the value of implementing the health care 
intervention identified as effective? 
In order to meaningfully apply the VOIM framework the selected reviews also were required 
to meet the following three criteria:  
 The Cochrane review draws unequivocal conclusions regards the clinical benefits of 
one or more healthcare interventions;  
 An existing UK based assessment of cost-effectiveness study that evaluates one of the 
recommended interventions and all relevant comparators;  
 The recommend intervention is cost-effective at threshold of £30,000 per QALY and 
reports either incremental QALYs and costs or NMB.  
The four included Cochrane reviews were:  
Review of anti-VEGF treatments for diabetic macular oedema (DMO);123  
Review of interventions for preventing falls in older people living in the community;43  
Review of statins for the primary prevention of cardiovascular disease (CVD);124 
Review of collaborative care for depression and anxiety problems.125 
To assess the impact of the Cochrane review, a model was run assuming an increase in 
utilisation upon publication of the Cochrane review.  This allows the estimation of utilisation 
both with and without the Cochrane review. To calculate the value of the increased utilisation 
the authors considered the additional QALYs generated and their value to the NHS assuming 
a threshold of £30,000 per QALY (i.e. that we are willing to spend £30,000 for one additional 
QALY of health). The value of this increase in health was then compared with the cost of 
carrying out a Cochrane review.  
Using the base-case assumption, the estimated health gains for the four case studies ranged 
from 116 QALYs from the review of anti-VEGF therapies for DMO to 15,816 QALYs from the 
review of statins for the primary prevention of CVD. The value in terms of net monetary 
benefit (NMB) which accounts for the value of the health gains and any additional costs of 
implementing the intervention ranged from a NMB of approximately £0.9 million for the anti-





Table 19: Impact of the Cochrane reviews to the NHS 
Cochrane reviews  
Assuming full 
implementation 








Review of anti-VEGF treatments 
for diabetic macular oedema123 
5,600 £48,444,564 116 £877,048 
Review of Interventions for 
preventing falls in older people 
living in the community43  
23,910 £740,601,295 1,558 £48,139,336 
Review of statins for the primary 
prevention of cardiovascular 
disease124 
534,406 £13,832,171,646 15,816 £409,227,452 
Review of collaborative care for 
depression and anxiety 
problems125 
58,254 £917,535,903 416 £6,487,256 
Source: Hodgson (2015)122 
These significant benefits were observed assuming relatively modest increases in 
implementation resulting from the Cochrane reviews of just 1% in our base case. In scenario 
analyses conducted assuming just a 0.1% increase in utilisation, the value of the realised 
benefits remained positive in three of the cases (the exception being anti-VEGF therapy for 
DMO) with estimated health gains ranging between 12 QALYs from the review of anti-VEGF 
therapies for DMO to 1590 QALYs in the statins review and NMB ranging from -£10,816 for 
the anti-VEGF review to £41 million in the Statins review.  
This study also highlights a number of 
drivers of value and the importance of 
considering the policy context. In particular 
the following factors are important when 
considering the potential value of any 
review or update:  
 The size of the eligible population;  
 Current and projected utilisation of the 
intervention; 
 Current and future NICE guidelines and 
technology appraisals;  
 Cost-effectiveness and resource 
implications of implementing the 
interventions. 
The analysis also illustrates some of the 
challenges of evaluating the value of 
The results of this study, while subject to a 
number of substantial caveats have shown 
that there is substantial value from 
implementing the recommended healthcare 
interventions both in terms of additional 
health benefits as well as net value to the 
NHS. A Cochrane recommendation regarding 
a cost-effective intervention needs only to 
lead to a fairly small change in practice to 
represent value for money. Further, these 
reviews can originate from any of Cochrane 
review groups including those based outside 
the UK. This comes however with a caveat to 




Cochrane outputs and in particular the difficulty of disentangling the influence of Cochrane 
from NICE guidance and other implementation activities. Due to these complexities it may be 
more appropriate for future research to consider how Cochrane is able to optimise their 
contribution to current processes of evaluation and implementation of interventions. 
Committee reflections 
The Committee considered that what this work is primarily contributing is increased 
quantification of benefit; the value resides not so much in the numbers themselves as in the 
way the attempt at greater quantification highlights issues/challenges. The study quantifies 
the value of Cochrane reviews in a manner consistent with NICE methods.  They use a dynamic 
model.  They identify the potential benefits of increasing implementation of interventions and 
some of the drivers of the benefit of reviews.  
The report distinguishes (at least initially) between helping to identify the most effective and 
cost-effective treatments, and promoting use by clinicians and policy makers.  Just as many 
factors and different pieces of evidence influence decision makers in making a 
recommendation, many factors influence the timing and extent of implementation of 
recommendations. In principle a Cochrane review might influence the recommendation, and 
given a recommendation the Cochrane review might influence the implementation of the 
recommendation. 
Taking the example of NICE technology appraisals, the manufacturer, and the ERG or AG, will 
generally systematically review evidence on treatment effect as a preliminary to estimating 
cost-effectiveness.126 If this is going to happen to what extent does an existing Cochrane 
review mean that the job is done for them or is facilitated?  If a new or updated review is 
undertaken, this raises questions regarding how much of the benefit of implementing an 
appropriate technology should be assigned to the Cochrane review as opposed to the NICE 
appraisal process. 
Cochrane reviews will only occasionally match the decision problem facing decision makers.  
Moreover, given the NICE approach to reviewing literature the Cochrane review might 
possibly speed up the review or provide some sort of validation of any review undertaken as 
part of the NICE process. There may (very occasionally) be cases where the result of a review 
is in effect new information but generally reviews are quite different from trials in this respect. 
The NICE process would have uncovered the relevant information and thus it really isn’t the 
case that the Cochrane review (even if cited) is influencing the recommendation.  On the 
other hand, possibly the implementation of a recommendation may be faster/greater when 
there is a supporting Cochrane review.  
Consider the example of aflibercept, an anti-vascular endothelial growth factor. The decision 
(by NICE) to recommend aflibercept for treatment of diabetic macular oedema (DMO) 
appears to have been driven by the combination of the VIVID and VISTA trial results and the 
economic modelling based on these trials.  Reading the review of the evidence and the 
discussion of further considerations (and given the Committee's experience of participating 
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in many broadly similar decisions) it really is hard to see how the Cochrane review123 made 
any difference to the decision making process.   
The authors of the CRD/CHE report122 have not given a justification for using £30,000 to value 
QALYs, and given recent York research and DH practice a value £15,000 might have been more 
appropriate. If the additional costs incurred due to the increased utilisation of anti-VEGF 
therapy are translated to QALYs using a more appropriate estimate of the opportunity cost in 
terms of displaced health benefits, implementation of a NICE recommendation of a 
technology with an ICER of £21,422 produces a net loss of QALYs.  Use of a λ of £15,000 in the 
aflibercept case turns the net monetary benefit from £5,061 to -£3,789. 
A key assumption is that 1% of any increased utilisation can be attributed to the Cochrane 
review. The authors argue (fairly reasonably) that they were unable to do other than make 
such an arbitrary assumption given the time available to complete the work.  The estimates 
of the benefits attributable to Cochrane reviews would obtain greater credence if there were 
supporting evidence from empirical studies of the determinants of increasing utilisation.  As 
the authors note they were particularly limited by lack of utilisation data. 
Where there is a very large body of literature a reasonable assessment of the evidence would 
be much harder without a review, and it seems more plausible that a Cochrane review may 
be influential.  Statins might seem to be such a case.  However, since there was no uniform 
welcome from the clinical community to the lowering of the risk threshold for prescription of 
statins (down to risk >10%) and already evidence of considerable variation in response to the 
previous guidance (statins where risk >20%), questions remain about the likely impact of 
Cochrane reviews on GP prescribing behaviour. 
The authors of the CRD/CHE study note that they haven’t accounted for the many 
uncertainties regarding their estimates. As they note this would be a standard part of any 
economic evaluation but that in order to do this they need access to a fully executable model. 
But even with a fully executable model the problem of uncertainty would still be great in that 
different analysts frequently come up with different models and different results when 
confronting the same decision 
problem and the same body of data. It 
needs to be stressed that estimates of 
incremental costs and incremental 
QALYs are generally sensitive to 
parametric and structural 
assumptions. 
The authors note that the study design 
is based on choosing studies with 
evidence of cost-effectiveness and of 
course many reviews do not have such 
evidence and thus cannot be assessed 
Clearly some reviews are much more likely to 
bring large benefit than others.  To what extent 
can these be identified in advance (for example, 
based on number of patients, extent of 
uncertainty, alternative treatments etc.)? Cross-
subsidising reviews which do not have a 
reasonable prospect of producing a positive net 
benefit is not efficient unless it is impossible to 
distinguish in advance between those which are 




with this approach.  Presumably a similar methodology could be used to identify the net loss 
of benefit when utilisation of a non-cost-effective intervention increases as a consequence of 
a Cochrane review. The Committee have no evidence regarding such net losses but perhaps 
it should be recognised that reviews could produce negative net monetary benefits.  As the 
authors note, the four examples are necessarily unrepresentative because of the need for a 
reliable and fully reported cost-effectiveness analysis.   
There is a temptation to point to one or two “blockbuster” reviews which by themselves 
justify the use of NIHR support for Cochrane reviews, that is, the estimated value of these 
reviews far exceeds the total cost of all of the Cochrane reviews. This might be appropriate if 
we are drilling for oil and no one site is a better prospect than any other. But perhaps the 
situation is more akin to a drug which is more effective in some sub-groups than in others. It 
is not a good use of resources to treat all because the total benefit exceeds the total cost, at 
least not if we can identify sub-groups where the costs exceed the benefits. Some Cochrane 
reviews such as one about “Chinese herbal medicine in the treatment of ectopic pregnancy” 
(DOI: 10.1002/14651858.CD006224.pub3) would be considered by many as inappropriate use 
of resources if prepared with support from NIHR funding. 
A limitation (with respect to our broader purpose) is that there is no analysis or discussion 
regarding the NIHR infrastructure support for Cochrane activities. The emphasis is on the 
value of individual reviews versus an estimate of the cost of those reviews.  This engages 
broader issues than were in their remit.  Taking the overall resource for infrastructure, to 
what extent can it be or should it be allocated to different Cochrane groups or indeed 
different Cochrane reviews? It seems unlikely that costs are not to some extent variable 
rather than fixed. It should be possible to estimate what part of the infrastructure support is 
fixed (unrelated to whether one or twenty groups are supported) and what part varies by the 
number of groups supported.  Is it feasible to identify the likely value of reviews produced by 
different groups and thus identify groups which merit NIHR support and ones that do not? 
Going further, it seems plausible to suggest that particular reviews are more likely to 
represent a good use of resources and others much less likely. If these could be identified it 
raises the question should the funding of individual groups reflect this anticipation? These 





Case studies of the economic impact of selected systematic reviews: 
Main points 
 Very selective information was available for this exercise. 
 For Cochrane to represent value for money Cochrane would only need to 
recommend a small number cost-effective interventions a year.  
 However, Cochrane needs to avoid cross-subsidisation i.e. ‘if one high impact 
review to save the NHS money, it makes all reviews worthwhile’ is not the correct 
message to portray. 
 It would be useful to see more Cochrane work incorporating economic evaluation 
to determine whether reviews lead to savings in the NHS.  
 Cost savings are not the only possible outcome. Methods may show effective 
treatments which cost the NHS money. 
 Reviews also exist to evaluate standard practice, which could result in savings to 





CHAPTER 5 - COCHRANE STRATEGY AND THE NHS 
 
Overview 
This chapter will discuss stakeholders’ feedback, Cochrane’s strategic plans and its relation 
to the NHS, and propose changes in reporting and monitoring processes between 
Cochrane UK and NIHR. Key points include: 
 The findings from Stakeholder interviews 
 The Cochrane Strategic Plan, and its relevance to the NHS 
 The role of Cochrane UK in meeting key clinical and policy issues in the NHS 
 Timeliness and up-to-dateness of reviews 
 Centralisation or decentralisation in Cochrane 
 Changes in reporting and monitoring processes between Cochrane UK and NIHR 
 
Report from Stakeholder interviews 
The themes from these interviews,2 in most cases, added weight to existing findings of this 
committee report and were an interesting snapshot in time of how Cochrane and is perceived 
in the UK. Thirty-four interviews were conducted during November and December 2015 with 
a range of Cochrane review users and producers, many of whom have multiple roles and 
interests in evidence synthesis and how this is used in health care in the UK.  An overarching 
theme from the interviews was that this NIHR investment in Cochrane had affected culture 
change in the NHS towards more evidence use in decision making. Most of the interview 
sample described the current NIHR spend on Cochrane therefore as good value for money. 
Cochrane is a trusted and valued source of evidence for many NHS health professionals, 
technical experts developing clinical guidance and information producers and information 
intermediaries e.g. bloggers.  It is also a trusted source of evidence for another group of 
people, but they find it more challenging to use in practice, namely health commissioners, 
policy developers, NHS managers and patients and the public and they value it less because 
of this. 
Cochrane reviews are seen as a quality product with a robust process underpinning their 
production.  The identity and brand is strong and visible to those who are research aware, but 
less so to those that are not.  Relevance of Cochrane reviews is an issue for some of this 
sample, and despite the quality of the product Cochrane reviews will have limited value if 
they do not address questions of importance and relevance to the NHS.   
Cochrane reviews are well received when they have clearly described interventions, are not 
too narrow in scope, address current and ongoing uncertainty, explain the treatment effect 
(or not) simply, and attempt to place the review in context.    
It is encouraging to see Cochrane UK’s efforts in using social media as a channel for 
communicating and providing context for the results and implications of Cochrane reviews, 
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especially for an NHS audience.  Some UK review groups are perceived as risk averse in having 
a public conversation about their reviews, preferring to post a review and hope that there is 
interest. 
There was no consensus about who the most important users of Cochrane Reviews were but 
interviewees were interested in having a dialogue with Cochrane about targeting users with 
Cochrane products that would be particularly useful in NHS decision making and policy 
development. 
There was a certain amount of push back about Cochrane's policy of focussing on high quality 
randomised controlled trials for reviews ('gold standard').  Many were interested in exploring 
how to incorporate different types of primary research; pragmatic trials and realist 
evaluations of treatments, qualitative research, cohort studies and large data sets (such as 
the National Joint Registry).   
Perhaps the biggest challenge for Cochrane is getting the balance right between prioritising 
reviews and review updates of high importance and relevance to the NHS, rapid reviews to 
assess critical and time sensitive questions, and managing the numbers of empty reviews. 
Interviewees welcomed this review and the close analysis of value to the NHS and the 
exploration of how to measure this in the future. The full report2 is included in the Appendix 
11. 
Cochrane’s Strategic Plan 
The Strategy to 2020 establishes Cochrane’s aspirations and priorities for the next five years 
and sets out how they plan to achieve their vision. Within the context of Cochrane’s mission 
it is based around achieving four key goals. 
Cochrane’s key goals of the 2020 Strategy 
GOAL 1: Producing evidence 
To produce high-quality, relevant, up-to-date systematic reviews and other synthesised 
research evidence to inform health decision making. 
GOAL 2: Making our evidence accessible 
To make Cochrane evidence accessible and useful to everybody, everywhere. 
GOAL 3: Advocating for evidence 
To make Cochrane the ‘home of evidence’ to inform health decision making, build greater 
recognition of our work, and become the leading advocate for evidence informed health 
care. 
GOAL 4: Building an effective and sustainable organisation 
To be a diverse, inclusive and transparent international organisation that effectively 
harnesses the enthusiasm and skills of our contributors, is guided by our principles, 
governed accountably, managed efficiently and makes optimal use of its resources. 
These goals are structured as three interlocking areas of equal focus and priority (Goals 1-
3), underpinned by a fourth foundational area (Goal 4) designed to strengthen Cochrane 
and support our mission. 
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As of Spring 2016, a number of the key issues identified in this report are being addressed in 
the 2020 Strategy, but others are not mentioned at all. The table below gives an overview of 
how the 2020 Strategy relates to the priorities of the NHS at this point in time. It will be a 
great opportunity for Cochrane to show any major progress that has been made since Spring 
2016. The Committee recommends SRPAG should follow-up on these items in annual 
reporting, in their role to monitor contract compliance. 
Table 20: Relationship between 2020 Strategy and NHS priorities; Committee’s interpretation 
in Spring 2016. 
Priority for the NHS What’s in 2020? What is unclear/less optimal? 
Patient involvement 
 
We will implement our new 
partnerships strategy, and 
develop new partnerships with 
consumer networks, 
technology providers, and 
other organisations hosting 
the Global Evidence Summit in 
2017. 
We will create a more inclusive 
organisation by launching the 
Cochrane Membership 
Scheme and re-developing the 
Cochrane Community website 
around it. 
Details as yet unclear. 
Collaboration with NICE 
 
 Not addressed. 
UK NHS and public/patient 
frontline 
 
 Not addressed. 




We will improve the Cochrane 
Review prioritisation list by 
increasing the transparency of 
each new entry, incorporating 
more priorities identified by 
external parties to ensure that 
it reflects global needs, and 
providing more opportunities 
for competent potential 
author teams and individuals. 
A paper explaining the 
rationale for revisions to list 
and proposed changes is 
published by March 2016. 
 
Details as yet unclear. 
Cochrane Response and 
Cochrane Innovations: both 
new developments appear to 
be in their infancy. 
The requirements for a topic 
to be deemed as high 
importance remains opaque, 
and fundamentally the funder, 
NIHR, has an expectation that 




Priority for the NHS What’s in 2020? What is unclear/less optimal? 
Keep more reviews up-to-date We will develop and begin to 
implement a comprehensive 
updating strategy for Cochrane 
content to ensure that high 
priority reviews are kept up-
to-date. 
Talks about keeping priority 
reviews up-to-date. The 
challenge to keep all reviews 
up-to-date remains. 
Prepare reviews more rapidly We will address the challenge 
of improving timeliness of 
review production by re-
evaluating the Cochrane 
editorial process and 
supporting pilot projects that 
improve production efficiency, 
author and editor experience, 
and review quality. 
Details as yet unclear. 
Cochrane Response and 
Cochrane Innovations: both 
new developments appear to 
be in their infancy. 
Use best available evidence, 
beyond RCTs 
 
 Not addressed. 
Role and structure of CRGs 
and Editorial 
We will implement changes to 
Cochrane Groups’ structure 
and functions to ensure our 
organisational structure is 
optimally aligned to 
Cochrane’s mission and goals. 
New accountability, reporting 
and support structures and 
processes are in place 
between the Central Executive 
Team and Groups. 
New managerial, reporting and 
support structures and 
processes are working well to 
support Cochrane Group 
transformation and normal 
work targets. 
Details as yet unclear. 
Training We will improve our training 
resources by establishing a 
new online learning 
environment. We will expand 
the support we provide to 
Cochrane editors by delivering 
a programme of training and 
accreditation for them. 
Details as yet unclear. 
 79 
 
Priority for the NHS What’s in 2020? What is unclear/less optimal? 
We will engage with our users 
to bring the concepts and 
methodologies of evidence 
synthesis into mainstream use 
beyond the research and 
medical communities, so that 
people know why and how 
evidence should be used to 
inform their health decision-
making. 
Governance We will improve the 
effectiveness of Cochrane’s 
governance by finalising and 
implementing a new 
governance structure, 
including a newly re-formed 
Governing Board (formerly 
Steering Group). 
Needs to make sure that an 
adequate number of non-
Cochrane stakeholders are 
included. 
Transparency We will increase the 
transparency of the 
organisation’s governance and 
improve the opportunities for 
any contributor to participate 
in governing the organisations 
and/or to be appointed to a 
leadership position. 
Details as yet unclear. 
Financial stability We will strengthen Cochrane’s 
financial position by 
diversifying and expanding our 
funding base, both at core and 
group level. 
Details as yet unclear. 
Meeting key clinical and policy issues in the NHS 
Timeliness of review production is essential to ensure the relevant, rigorous evidence is 
available within an appropriate timeframe to meet the demands of the policy or decision-
making cycle.127 The topics of reviews not only need to match up with NHS and patient 
priorities, the timeline for delivery of complete and up-to-date evidence needs to align with 
policy and decision-making processes.127 It is essential that Cochrane avoids being 
comfortable and complacent, as it needs to think about radical news ways to meet current 
demands as well as future challenges.10  One of the challenges facing Cochrane in the future 
is how to adapt the mission of Archie Cochrane and NIHR in a compatible way; a re-think is 
needed to face the modern challenges, which are difficult.10 
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Time-to-publication and currency (up-to-dateness) of new reviews remain crucial matters 
faced by NIHR-funded CRGs, and Cochrane in general. The CEU assessed the median time-to-
publication (TTP) of a sample of SRs produced by NIHR-funded CRGs. Time-to-publication was 
defined as meaning the period in months between protocol and publication of the completed 
SRs. Analysis of a sample of SRs completed in 2013 showed a median TTP of 30 months, which 
improved somewhat by the 2104 sample (median: 23). The overall median TTP for both 
samples was 23 months (range: 8 to 103).4 Similarly the time-lag between the search date 
and publication of the completed SR was considerable; 24 weeks in 2013, 27 weeks in 2014, 
and 25 weeks overall. There was substantial variation between assessed reviews, with 
number of weeks between the date of searching and publication of the review ranging from 
two weeks right up to 195 weeks (2013 and 2014 combined).4  
Table 21: Time between protocol and searching and publication of completed NIHR-CRG SRs 
CONFIDENTIAL CONTENT FROM COCHRANE – MADE AVAILABLE TO NIHR 
Source: Cochrane Collaboration (2015)4 
Cochrane acknowledged the challenges of ensuring SRs are published in a timely manner, 
giving the following reasons:4 
 Reliance on a predominantly volunteer contributor base; 
 A culture that prides itself on an inclusive approach to commissioning and the provision 
of extensive author support, leading to ‘bottle-necks’ 
 Reviews becoming more complex and challenging to produce as methodology 
advances 
 Technology not keeping pace with needs4 
Reliance on contributors that often have other priorities, or have no grant for their salary 
to carry out the review may not be quite the same as a volunteer contributor base. 
Despite delays in publication, exemplars of good practice exist, such as the review of 
bevacizumab for macular degeneration. This review produced by the NIHR-funded Eyes 
and Vision CRG, was completed three months after publication of the protocol.128 An 
analysis of TTP from 2005-2014 across all UK-based CRGs† showed considerable variation 
between CRGs and within CRGs over the time period.  
As the methodological requirements and quality assurance procedures involved have 
become more intensive, TTP for some groups has increased since 2005. Other show 
improvements in TTP, perhaps as a consequence of capacity building and increased 
expertise within the teams. Overall mean TTP for all UK-based CRGs and for all years was 
24 months. While this represents a considerable time delay in review production, 
especially in meeting stakeholders' needs for timely evidence to inform policy and 
decision-making; it may also be indicative of increases in workload, increased 
                                                          
† This included three non-NIHR-funded CRGs: Developmental, Psychosocial and Learning Problems; Stroke and 
Vascular CRGs. The analysis did not include the EPOC CRG, now funded by NIHR. 
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requirements for methodological rigour, greater complexity in review topics and scope, 
and an ongoing process of enrolment and training of volunteer review teams. 
Figure 14: Mean time to publication (TTP)‡ for UK-based CRGs§: 2005-2014 
 
Source: Cochrane Collaboration (2015)4 
A recent study was undertaken by NETS-CC in partnership with Queen's University, Belfast,129 
investigating the impact of NIHR Cochrane Incentive Scheme funding on TTP.129 The figure 
below shows time-to-publication was up to 2.5 years faster for Incentive Award-funded 
reviews than non-awarded reviews. 
  
                                                          
‡ TTP defined as elapsed time (months) between protocol and review publication. 
§ This included three non-NIHR-funded CRGs: Developmental, Psychosocial and Learning Problems; Stroke and 














Figure 15: Time-to-publication (TTP) for Cochrane Incentive Award-funded reviews compared 
to non-awarded reviews 
 
Source: Bailey S, Clarke M. & Zhang YG (2016) 129 
Publish when ready 
In 2013, Cochrane launched a new continuous publishing model for CDSR, known as Publish 
When Ready" (PWR).130 The PWR approach enabled immediately availability of new and 
updated reviews; alternatively, release of new publications could be scheduled by the CRG 
editorial team. This publication model allows continuous updating of CDSR and minimises the 
publication time lag which is inherent in resources published quarterly. 
Priority list of titles 
“In January 2015 the Cochrane Priority Reviews List was launched, with approximately 300 
reviews and updates. The list has become a ‘living’ record of Cochrane’s attempt to identify 
titles that are of greatest importance to our stakeholders and are most likely to impact 
significantly on health outcomes worldwide.  The list has evolved, with almost a 100 titles 
added, 28 new protocols published and 82 reviews and updates published between January 
2015 and March 2016. The list is updated in real time by staff at the Cochrane Editorial Unit 
(CEU) and a version is published on Cochrane.org once every two months.” 
“The current process is reliant upon Cochrane Reviews Groups (CRGs) undertaking their own 
prioritisation exercises, with little or no input from the Cochrane Central Executive Team (CET) 
and no participation by other groups within Cochrane.” 
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“To address the issues outlined above we are introducing a number of changes to the way the 
Cochrane Priority Reviews List is compiled, with a view to streamlining and focusing the list, 
ensuring that Cochrane priorities explicitly address the needs of global healthcare decision 
makers and promoting wide participation by appropriately skilled authors. We will: 
1. Actively seek referrals from other groups within Cochrane, such as Fields, Methods 
Groups and Centres. 
2. Reduce the size of the list overall and impose a maximum number of titles per group.  
3. Require that submissions to the Cochrane Priority Reviews List be accompanied by 
documentation that gives a rationale for inclusion, plus supporting evidence for the 
importance of the titles(s).  
4. Engage with external partners such as World Health Organisation (WHO) and Pan 
American Health Organization (PAHO) to improve our ability to reflect priorities that 
represent global. 
5. Encourage all groups to engage in a formal prioritisation process based on 
consultation with one or more external stakeholders groups such as funders, health 
professionals, consumers, guidelines agencies or healthcare policy makers.  
6. Encourage CRGs to propose submit titles that are open to new authors or author 
teams, conditional on them having the required skills and knowledge. 
7. An expectation that CRGs will 'fast track' titles on the Cochrane Priority Reviews List 
through their editorial processes. 
8. Support CRGs in creating impact plans for their priority reviews.  
9. Support CRGs by providing a screening service for priority reviews where appropriate.” 
The above text is from the CEU's outlined plans.131  
It is unclear how the Priority Setting Methods Group has been involved in this prioritisation 
process. There is also no mention of taking NHS priorities into account, on the contrary, global 
organisations like WHO are likely to have very different priorities. Many CRGs may see this as 
a tick box exercise with little purpose and little practical help in strategic prioritisation of 
topics and reviews. 
NIHR has funded Warwick Business School to do the project “Improving the capabilities of 
NHS organisations to use evidence” (Ref HS&DR - 12/5002/20).  This project focuses on what 
forms of evidence are used by NHS commissioning groups, when it is used and how. It would 
be good if Cochrane and Cochrane UK note this project and take account of its findings. 
Centralisation or decentralisation? Cochrane's proposed plans for Group level change: 
Review of the structure and function of Cochrane Groups 
Cochrane has initiated a consultation about changing the structure and function of CRGs and 
their relation with the CEU.132 The Committee welcomes that Cochrane has opened up the 
debate around centralisation versus decentralisation of the CEU. This will highlight the 
benefits and problems with both options. Decentralisation problems may include difficulties 
maintaining standards and quality, with no improvement on timeliness. Equally, 
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centralisation may improve the quality, but result in far less timeliness, delaying processes 
with greater central editorial steps. Prioritisation centrally may dramatically help CRGs in 
terms of workload, however potentially lacks the individual topic area expertise.  
The Committee considered that economies of scale can be gained from CRGs working 
together, this is an important aspect and needs to be seriously explored. Centralisation versus 
decentralisation is a core consideration for Cochrane’s future and should be transparently 
and swiftly discussed. A clear argument for why Cochrane is proposing splitting development 
and editorial functions as a key to solving the problems needs to be made. The Committee 
expects some intensive discussions within Cochrane about this, hopefully resulting in a 
sensible way forward with focus on maximising in-country impact of their reviews.  
Furthermore, clarifying areas for consistency and areas for flexibility is critical to Cochrane’s 
roles and functionality moving forward. Cochrane has to set definitions regarding where CRGs 
can have flexibility and where they have to behave in consistent way, e.g. with prioritisation. 
The nature of funding sources will dictate where responsibilities lie and funding sources 
should be openly considered when thinking about future direction of travel, capacity and 
accountability. It seems currently unclear how infrastructure of fewer larger groups will be 
funded. Will it follow the (presumed) external grant income?  
There appears to be a clear emphasis on doing fewer reviews than Cochrane have said in the 
past, but there is not an explicit decision to abandon comprehensiveness. Cochrane should 
clarify its strategy concerning coverage, so that funders and users know what to expect in the 
near future. 
Planned developments in reporting and monitoring processes between Cochrane and 
NIHR 
The UK NIHR-funded CRGs are currently monitored via annual reports submitted on 1 May 
each year to NETSCC. The reports contain qualitative reporting against the objectives set in 
the business plan agreed as part of the contracting process with the UK Department of Health, 
and quantitative data based on outputs. In order to monitor the performance of each group, 
a formula is used to calculate a score, which in turn is used to rank groups against each other. 
The NIHR QQR Panel had previously made a recommendation to enhance these metrics with 
additional points aligned to the NIHR’s “Adding Value in Research Framework”, and this has 
been incorporated in to the CEU model, specifically the following. 
1. Rating review groups should not be dominated by the volume of output alone, but 
should consider other aspects such as quality, relevance, utility and complexity 
2. How groups are monitored should be transparent to all 




Cochrane are intending to undertake a governance review of CRGs in line with the parallel 
work in the rest of Cochrane. How Cochrane approach performance will inevitably form a part 
of this, but is likely to consider:  
 Clear evidence that the title is a high priority to key end users: patients, health 
professionals, local policy makers and other international health systems 
 High adherence to Cochrane standards and expectations (Methods Expectations of 
Cochrane Intervention Reviews – MECIR) 
 Reviews that include a GRADE analysis and summary of findings table to facilitate 
incorporation into clinical practice and guidelines 
In addition, there are other characteristics that are consistent with Cochrane Strategy and 
desirable to funders and decision makers: 
 Reviews that include appropriate and useful enhanced features e.g. improved 
coverage of harms via inclusion of non-randomised studies, or multiple treatment 
meta-analyses 
 Reviews of complex interventions e.g. health service delivery reviews  
 Reviews that address different types of questions that are a high priority to end users 
 Reviews that are produced in a timely and efficient manner  
 Reviews that directly lead to new primary research 
 Reviews that are accompanied by a clear dissemination/knowledge translation plan 
The new model is currently being piloted within Cochrane and will hopefully be agreed in 
2016.  It has been agreed to run the current NIHR reporting mechanism in 2016. 
The Committee feels that key performance indicators should focus on measures of impact; 
emphasising the need for groups to plan and think more strategically moving forward in order 
to maximise impact on the NHS. 
Metrics need refinement to more precisely capture possible impact, quality, size and 
complexity of reviews. Although outputs, quality and activities remain important, more 
emphasis on measures of impact is advisable for future evaluations of NIHR Cochrane funding. 
Impact should be assessed in terms of impact on policies, practice change, culture change, 
and methodology change. For realising such impact, improving communication with the 
public, health professionals and policy makers will be key for Cochrane UK, individual review 
groups, and Cochrane worldwide. 
The Committee also recommends public disclosure of CRG performance. A number of low 
quality Cochrane SRs exist and can be identified from existing and future MECIR and 
readability studies. Currently, although these exercises have provided invaluable insight into 
the CRGs who perform well consistently producing high quality reviews, the Committee notes 
a lack of transparency in disseminating the findings. It remains unclear what remedial action 
was put in place to support those CRGs performing less favourably. 
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Current and planned developments in Cochrane: Main points  
 The Committee recommends that Cochrane maintains its focus on full, timely and 
relevant systematic reviews. Don't invent new products to cut down production 
time. This is echoed in stakeholder feedback; a new output is not required, just the 
existing product delivered quicker and with high relevance. 
 Cochrane should continue work on developing expertise and processes, to get 
better and quicker at producing reviews. 
 Cochrane should revisit some of its goals. There seem to be many different 
objectives in many areas. However, the Committee feels that an explicit focus is 
needed on topics relevant to decision making for patient care, as a primary goal. 
 The strategy to 2020 should determine and highlight Cochrane’s niche and unique 
selling points, and provide clear direction on/towards these. 
 Centralisation vs decentralisation is a core consideration for Cochrane’s future and 
should be transparently and swiftly discussed. Clarifying areas for consistency and 
areas for flexibility is critical to Cochrane’s roles and functionality moving forward. 
 The nature of funding dictates where responsibilities lie and funding sources should 
be openly considered when thinking about future direction of travel, capacity and 
accountability. 
 Key performance indicators should focus on measures of impact; emphasising the 
need for groups to plan and think more strategically moving forward in order to 




CHAPTER 6 - THE VALUE FOR MONEY OF NIHR COCHRANE 
INVESTMENT AND POINTS TO NOTE FOR THE FUTURE 
Overview  
This chapter deals with the question whether NIHR funding for Cochrane should be 
continued. 
 Cochrane has been good value in the past, but could it have been better value? 
 Cochrane has had value in the last five years, but was this as good value or as 
impactful as the previous ten years? 
 Cochrane still represents good value for money when compared to its competitors, 
however does funding fit and is it effectively occupying a niche? 
 Would less funding undermine the Cochrane product? 
 Should other options, i.e. more targeted funding or re-distribution of funding be 
considered? 
Cochrane has been good value in the past, but could it have been better value? 
Impact is hard to demonstrate, but the Committee feels that NIHR investment in Cochrane 
infrastructure has made large (both direct and indirect) contributions to: 
 A culture change in the use of evidence to support decision making 
 Reviews in some areas of high importance to the NHS 
 Synthesis methods development 
However, the value of the investment has been limited to some extent by: 
 The fact that Cochrane’s ad-hoc responsive approach to review topics generated by 
authors interests has not secured, after 20 years, a comprehensive set of reviews, or 
a guarantee that NHS priorities are met 
 Variable performance of CRGs in outputs, and variable processes 
 Methods (focus on randomised trials) that exclude consideration of important aspects 
of decisions (harms, patient experience and economics, for example) 
 Less secure infrastructure funding in other countries 
CRGs and Cochrane UK have spent a lot of time training and building capacity within in CRGs, 
the wider research community, and the NHS. This has helped the culture change in the use of 
evidence to support decision making, and should continue to be encouraged and expanded. 
Cochrane as an organisation has acted as a key driver of research synthesis methods 
development and actively promoted adoption of many aspects of systematic review 
methodology. Examples of innovations developed within Cochrane and adopted by reviewers 
on a global scale include: 
 Cochrane tool for assessing risk of bias in randomised trials91 
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 Cochrane risk of bias assessment tool: for non-randomised studies of interventions 
(ACROBAT-NRSI)92 
 Cochrane Highly Sensitive Search Strategy (HSSS) for identifying randomised 
controlled trials in Medline93 
However, of concern are empty reviews with overly restrictive inclusion criteria concerning 
the types of studies, such as only RCTs, in situations where other types of studies addressing 
the question exist. 
Furthermore, Cochrane has a number of resources, generated with support of NIHR funding, 
which are not fully accessible, such as specialised registers. The Committee recommends that 
Cochrane looks into ways to increase sharing of resources and collaboration. 
Cochrane has had value in the last five years, but was this as good value or as impactful 
as the previous 10 years? 
One evaluation discussed in this report showed that 88% of Cochrane reviews are rated to 
have a low risk of bias, compared to only 12% of non-Cochrane SRs. However, the group of 
non-Cochrane reviews is a very mixed bag, very likely to contain reviews from for example 
leading HTA and reimbursement agencies which have similar or even higher quality than 
Cochrane reviews. Another finding that 8% of Cochrane reviews in two topic areas were 
assessed at high risk of bias was in line with the findings of the CEU's MECIR Screening Project 
which found 5% of NIHR-funded SRs assessed required major amendments. 
It is apparent that CRGs face challenges in review capacity to deal with large numbers of 
reviews assessed as in need of updating. During the 2014 assessment process, 1,250 reviews 
were assessed as requiring an update, which were either in-progress or awaiting sufficient 
resources to complete them. 
There are tensions between CRG’s and central editorial processes. It is for Cochrane to 
address these issues, with adequate attention paid to maintaining the motivation of CRG staff. 
Although the Committee is aware of many expressions of positive experiences, there are also 
tensions between authors and CRGs, especially where prospective reviewers are dismissed 
because of CRG workload and where long delays occur in dealing with protocols and draft 
reviews; this means that NIHR investment is put at risk where reviews cannot get through the 
editorial pipeline in reasonable time. Data about workflow delays should be included in NIHR 
monitoring requirements. 
Although Cochrane’s MECIR screening project has provided invaluable insight into the CRGs 
who perform well consistently producing high quality reviews, the Committee notes a lack of 
transparency in disseminating the findings of these exercises. It remains unclear what 
remedial action was put in place to support those CRGs performing less favourably. 
Cochrane should further explore ways of reaching wider audiences and interacting more. 
Groups should be encouraged to increase liaisons with social media and infomediaries. 
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Cochrane still represents good value for money when compared to its competitors, 
however does funding fit and is it effectively occupying a niche? 
In the systematic review world, Cochrane is a highly respected player. Preparing systematic 
reviews is nowadays a highly competitive field. 
People support Cochrane as the first port of call and do not want to see Cochrane go. 
Cochrane is seen as a trusted source by healthcare professionals, clinicians, guideline 
developers, information producers and infomediaries. Cochrane evidence is also valued by 
health commissioners, policy developers, NHS managers and the public, however they find it 
more challenging to use in a practical sense. Consequently, they value it less than could be 
the case, leaving room for additional improvement. 
There are advantages of Cochrane being a reviewer-driven organisation and there are few 
alternatives. A key benefit of Cochrane's collaborative model of working alongside volunteer 
reviewers who are also healthcare professionals is that the voluntary review authors based 
within the healthcare system have in-depth and acute knowledge of their particular topic of 
interest that top-down researchers may not be aware of. The reviewer-driven approach 
enables insight and innovation at this level, increasing relevance to the NHS and impact on 
health care. 
The Committee observes that Cochrane’s terminology around ‘volunteer’ may be dated. A 
number of Cochrane processes don’t entirely align with the idea of volunteerism. It is 
important to acknowledge that there are a number of full-time paid individuals working in 
Cochrane, and a number of academics gaining from Cochrane. Conversely, the true volunteer 
nature of consumers is perhaps being under-used, with varying levels of good practice across 
groups. Further focus on consumer value and use is recommended. 
The NIHR invests a great deal of time and money into gaining patient and public involvement 
in its research. Cochrane do not necessarily always take advantage of this but should. For 
example, Cochrane could make greater use of horizon scanning and literature review rather 
than starting prioritisation exercises from scratch. NIHR could help with priority setting work 
using already existing resources, such as HTA PG that should be tapped into. The Committee 
recommends SRPAG should follow-up on these items in annual reporting, in their role to 
monitor contract compliance. 
The Committee acknowledges that Cochrane is a worldwide organisation, and therefore focus 
on the NHS should not be exclusive. However, to justify considerable NIHR funding, the scope 
of Cochrane reviews should be optimised as much as possible to the NHS and commissioners' 
needs. Improving timeliness and hitting policy decision windows better will increase impact 
and use of reviews. 
The Committee also felt that the relationship between Cochrane and NICE and similar 
agencies should be encouraged and emphasised further; strengthening links, routine 
collaboration, and utilising each other’s products and sharing of information. This would 
strengthen Cochrane’s position relative to its many competitors. 
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Would less funding undermine the Cochrane product? 
NIHR have committed £16 million funding for CRGs over the five year contract period (2015-
2020); in addition Cochrane UK is funded by NIHR and there are Cochrane Incentive Awards 
and Cochrane Programme Grants available. This report discussed that there is substantial 
value from implementing some healthcare interventions recommended by Cochrane both in 
terms of additional health benefits as well as net value to the NHS. Clearly some reviews are 
much more likely to bring large benefit than others.  If such reviews can be identified in 
advance, inefficient cross-subsidising of reviews which do not have a reasonable prospect of 
producing a positive net benefit could be avoided. However, currently there is no easy way to 
distinguish in advance between those which are likely to be cost-effective and those which 
are not. 
Given that Cochrane is receiving protected non-competitive ring-fenced funding, the 
Committee recommends that it needs to be continually evaluated and justified. NIHR 
Infrastructure funding should be linked to key performance indicators. 
The Committee welcomes Cochrane’s steps towards open access, but thinks it is vital to see 
more clarity in relation to plans for open access and alternative funding models for Cochrane 
should revenue be lost from the library. Although this transformative initiative will enable 
freely available Cochrane SRs for all globally, there are concerns regarding possible impact of 
loss of Cochrane Library royalties on the financial stability of Cochrane. Funders and Cochrane 
need to work together, and transparency in proposed plans is encouraged.  
This is also extended to the 2020 Strategy, with the Committee recommending that it should 
be reviewed carefully and individual points identified for clarification, where the vision of 
Cochrane at 2020 is still unclear. 
Should other options, i.e. more targeted funding or re-distribution of funding be 
considered? 
The Committee felt that it is important to consider whether there are better ways to spend 
the NIHR funding in Cochrane, but equally it is vital to consider the wider cost and impact of 
not producing Cochrane reviews. Both questions are difficult to answer. To ensure 
responsiveness and coverage for the NHS, the Committee recommends to continue funding 
Cochrane and consider increased funding if it will guarantee better coverage. However, this 
funding should be linked to key performance indicators to ensure optimal value for money. If 
warranted, variation of funding be it either increase of decrease should be swiftly 
implementable.  
The Committee is well aware that Cochrane is a worldwide organisation and that the activities 
of UK based CRGs have a worldwide focus. Funding UK based CRGs gives benefits worldwide, 
and simultaneously the NHS benefits from Cochrane work done elsewhere in the world. 
Many NHS staff contribute to Cochrane. This is a good thing, but we need to be conscious of 
the opportunity costs of using clinicians, nurses and other health care professionals for 
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preparing systematic reviews. It will be reassuring if Cochrane can increasingly demonstrate 
impact. 
The Committee recommends that key performance indicators should focus on measures of 
impact; emphasising the need for Cochrane to plan and think more strategically moving 
forward in order to maximise impact on the NHS. Key performance indicators include impact 
and prioritisation, and linked to these, relevance and timeliness. Impact can only happen if 
the quality of outputs is high. 
Metrics need refinement to more precisely capture possible impact, quality, size and 
complexity of reviews. Although output numbers and activities remain important, more 
emphasis on measures of impact is advisable for future evaluations of NIHR Cochrane funding. 
Impact should be assessed in terms of impact on policies, practice change, culture change, 
and methodology change. For realising such impact, improving communication with the 
public, health professionals and policy makers will be key for Cochrane UK, individual review 
groups, and Cochrane worldwide. 
The Committee recommends public disclosure of CRG performance. A number of low quality 
Cochrane SRs exist and can be identified from existing and future MECIR and readability 
studies. Currently, although these exercises have provided invaluable insight into the CRGs 
who perform well consistently producing high quality reviews, the Committee notes a lack of 
transparency in disseminating the findings. It remains unclear what remedial action was put 
in place to support those CRGs performing less favourably. 
Cochrane UK functions as the "front door" contact for relationship building. A key area for 
expansion is to function as an interface between, and assist, groups and policy/decision 
makers e.g. NHS Commissioners in terms of deliverance – facilitating and enabling priority 
reviews to be completed and put mechanisms in place to deal with any delays. 
The Committee was pleased to see the announcement about replacing the current Cochrane 
Steering Group structure with a new Board. The current structure does not involve non-
Cochrane stakeholders and it is not quite clear who is in charge of what, also in respect of the 
chief executive officer and the editor. The Committee welcomes the intention to include more 




The value for money of NIHR Cochrane investment and points to 
note for the future: Main points 
1) The Committee recommends to continue funding Cochrane. However, this funding 
should be linked to key performance indicators to ensure optimal value for money. If 
warranted, variation of funding be it either increase of decrease should be swiftly 
implementable.  
2) A revised structure of Groups could impact dramatically on efficiencies, outputs and 
future funding models, and should be explored, and pursued more proactively by 
Cochrane. E.g. fewer, larger groups could overhaul efficiencies. 
3) In the Committee’s opinion, the past has shown good value, the present currently 
represents slightly reduced value than past time periods, and the future is currently 
unclear. 
4) Key performance indicators should be crucial in securing funding.  
5) Many recommendations may reflect or be in progress in line with the Cochrane 
strategy to 2020, however the Committee feel that progress needs to speed up, be 
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